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Abstract 
The effects of the chemotherapeutic agent vinblastine versus the low temperature of 277 
K on the structure of αβ-tubulin heterodimer were investigated by means of molecular 
dynamics simulations. Individual experiments have shown that vinblastine-bound 
heterodimer, and its apo structure under low temperature of 277 K, both undergo 
conformational changes toward destabilization of the dimer as compared to the apo 
tubulin at 300 K.  Both factors exhibit weakening the longitudinal interactions of tubulin 
heterodimer through displacing dimer interfacial segments, resulting in the dominant 
electrostatic repulsion at the interface of the subunits. The two independent factors of 
temperature and anti-mitotic agent facilitate folding alterations in the functional segments 
of H1-S2 loop, H3, H10 helices and T7 loop, which are known to be important in either 
longitudinal or lateral contacts among αβ-heterodimers in microtubule protofilaments and 
the depolymerization mechanism of microtubules. 
    Carbon nanotubes have become one of the candidates for transporting drugs to target 
sites, because of their size scale, huge surface area and high cellular uptake. Many 
experimental studies of carbon nanotube drug delivery have been performed in the past 
decade. The delivery studies of vinblastine and its target microtubule are important, 
because of the significant role of vinblastine in cancer therapy. However, the interactions 
between vinblastine and carbon nanotubes have yet to be investigated. The computational 
studies of the interactions between vinblastine and carbon nanotubes under different 
conditions are presented in this thesis. The vinblastine-carbon nanotube interactions have 
been studied from the following perspectives: loading capacity (one to three vinblastine 
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molecules loaded); tube structure (armchair, chiral and zigzag tubes); tube 
functionalization; and temperature variations (277 K and 300 K). The functionalization of 
carbon nanotubes strengthened the drug-carrier interactions of all systems at 300 K. The 
functionalized carbon nanotubes of armchair type were identified suitable for drug 
delivery at both 277 K and 300 K, due to the relatively strong drug-carrier interactions. 
The functionalized chiral nanotubes were found especially useful for delivery at 277 K 
due to the enhanced drug-carrier interactions at this temperature.
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CHAPTER 1  
 
Introduction 
1.1 Cancer 
Cancer is a class of diseases which can be traced back to alterations of specific genes.1-2  
Such genome alterations are progressively developed by accumulative exposure to 
carcinogenic agents including chemicals, viruses and other environmental factors, such as 
ultraviolet radiation in the case of skin cancer.3 Although the properties of cancer vary 
from one type to another, cancerous cells share some common features regardless of their 
tissues of origin. At the cellular level, the notorious characteristic of cancerous cells is 
uncontrolled growth. It is the way of responding to stimulatory or inhibitory growth 
signals that differs cancerous cells from normal cells, rather than the capacity of growth.4 
Stimulated by growth signaling molecules, such as diffusible growth factors, extracellular 
matrix components, and intercellular adhesion/interaction molecules, normal cells grow 
and divide at a rate comparable to their malignant counterparts; their growth and division 
are stopped by inhibitory growth signals under control. Conversely, cancerous cells can 
grow and divide even in the absence of the growth signaling molecules required for the 
proliferation of normal cells. They generate growth signals without depending on the 
signaling of normal cells and keep proliferating out of the control of normal cell 
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inhibitory signaling and, consequently, either a benign or malignant lump is formed at the 
growth site.2, 4 Chemotherapy and radiotherapy are conventional and powerful 
approaches for cancer treatment, in combination with tumor removal surgery.5-6 Both 
chemo- and radio-therapy are intended to block the fast growth of tumor cells. 
Chemotherapy suppresses the fast-dividing cancerous cells mainly through two strategies: 
interruption of DNA replication and perturbation on mitotic spindles.7 Radiotherapy, as 
another surgery adjuvant treatment, generates high-energy ionized particle to induce the 
breakage of single- and double-stranded DNA of cancerous cells.8 Under certain 
treatment, mitosis, the core part of cell proliferation, is arrested because the therapy-
induced programed cell death, also known as apoptosis, leading to the exit of the cell 
cycle.9 Therefore, tumor shrinkage is observed and proliferation of cancerous cells is 
gradually brought under control. Currently, chemotherapy still lacks specificity to target 
only cancerous cells without affecting normal cells. The shortcomings of commonly used 
anti-cancer therapeutics are seen from the side effects accompanied with the treatment, 
including symptoms such as nausea, hair loss and extreme fatigue.4  
1.1.1 Cancerous cells 
Apart from the loss of controlled growth, several other features also distinguish cancer as 
a class of complicated diseases. Tumor progression requires activated expression of the 
enzyme telomerase.2 Tumor cells failing to express telomerase would undergo telomere 
shrinkage, lose chromosome ends and, eventually, die out. Only tumor cells with 
reactivated telomerase expression undergo indefinite division. Normal cells, on the other 
hand, usually lack telomerase activity; therefore, the telomeres of chromosomes get 
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shortened after each division. When telomere shortening reaches a critical point, 
triggering the inhibitory signal to cease continued growth, the cell division process stops.2  
    The deep cause of uncontrollable cell growth lies in the mutations of DNA. Four types 
of genes control the cell division process: proto-oncogenes, tumor suppressor genes, 
DNA-repair genes and suicide genes.2, 10-11 Proto-oncogenes act as an accelerator to 
promote cell proliferations. Tumor suppressor genes, on the contrary, act as a brake to 
stop growth. The mutations occurring in proto-oncogenes and tumor suppressor genes 
lead to the conversion of proto-oncogenes to oncogenes, as well as the loss of function on 
controllable growth, and thus transform a cell from the normal state to the malignant state. 
Furthermore, the mutations on DNA repair genes deactivate their functions of damage 
repair and defect correction. If the damage is beyond repair, the checkpoint mechanism 
signals toward cell death.10 Mutations in suicide genes cannot perform the action of cell 
death called by the checkpoint mechanism, which gives the cell with unrepaired genetic 
damage a chance to escape apoptosis, continue cell division and transform into a 
cancerous cell. Cancerous cells thus undergo infinite proliferation, leading to the 
formation of a lump or a massive tissue.11 
    Another feature is that tumor cells have a special microenvironment different from 
normal cells, which triggers their independent growth. Tumor cells produce their own 
growth signals which are less dependent on exogenous growth stimulation, to interfere 
with the mechanism ensuring proper cell behaviors. The original site where cancerous 
cells grow is called the primary site. The new invaded sites are called secondary sites.12 
The invasion ability makes cancer cells spread to adjacent and distant tissues. Cancer 
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cells attach to a new site when the adhesion between cells and the extracellular matrix 
changes, and the interactions between cancer cells and primary sites are weakened. 
Cancer cells at the primary site send some pioneering molecules to nearby or remote sites 
to change the microenvironment, making it easier for tumor cells to attach. As cancer 
cells become aggressive, they spread and stick to normal healthy tissues and thus begin 
invasion to other sites. The uncontrolled growth on secondary sites rather than the 
primary site is the major cause of death.12  
1.1.2 Mitosis in normal eukaryotic cells 
The dividing cells go through a series of stages which are referred to as the cell cycle. 
The complete cell cycle includes “Interphase” and the “Mitotic phase” (M phase). Most 
of the time of the cell cycle is spent on the interphase; M phase, also known as the 
process of mitosis, accounts for only a small portion of the cell cycle.13 During mitosis in 
eukaryotes, a parent cell completes DNA duplication and the replicated chromosomes are 
equally segregated into two identical daughter cells at the final stage of M phase called 
cytokinesis. Although mitosis is a short stage of the cell cycle, it is further divided into 5 
sub-stages: prophase, prometaphase, metaphase, anaphase and telophase. When cell 
division starts, chromosomes encoded with genetic information are in the form of pairs of 
replicated sister chromatids linked by proteins called cohesins.13 During prophase, 
chromatids condense and the nuclear envelope breaks down so that condensed 
chromatids are released to the cytoplasm. At prometaphase, chromatids get attached to 
microtubules of the mitotic spindles through proteins called kinetochores. The mitotic 
checkpoint signaling is active at this stage. At metaphase, mitotic spindles direct 
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chromosomes to congress at the central plane known as the metaphase plate. The mitotic 
checkpoint signal decays and eventually deactivates, then the anaphase promoting 
complex, an E3 ubiquitin ligase, gets activated and triggers the next stage of anaphase.14 
Anaphase includes two steps: anaphase A and anaphase B. During anaphase A, the 
protease, called separase, cleaves cohesins and causes the separation of sister chromatids. 
Chromosomes segregate during this stage. At anaphase B, the mitotic spindles elongate 
and push the segregated identical chromatids toward each pole. Telophase is the final 
stage of mitosis; nuclear envelopes reform followed by the decondensation of 
chromosomes. The step of cytokinesis follows mitosis, where the cell is divided into two 
daughter cells that enter interphase.13-15 (Figure 1.1) 
 
Figure 1.1 Confocal immunomicrographs of HeLa cells with microtubules (green) and 
DNA (red) in the process of cell division. (A) interphase, (B) metaphase, (C) anaphase, 
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(D) telophase, (E) initiation of the middle-body formation and (F) cytokinesis. (From 
Stanton et al., 2011)14 This figure is adapted with permission. 
 
    The precision of chromosome alignment and segregation is crucial for the success of 
mitosis. A single error in the alignment or partitioning of chromosomes can prevent 
further progression of cell division, and lead to the arrested state ending in the mitotic 
checkpoint-induced apoptosis.  
1.1.3 Apoptosis 
Apoptosis, known as programmed cell death, is an essential process equally as important 
as cell division and cell migration. Apoptosis is a highly regulated self-destruction 
program to keep cell number and tissue size in rigorous control by eliminating over-
produced and dysfunctional (aberrant) cells. It is also a self-defense mechanism to 
minimize the potential risk to the integrity of a cellular environment.16 
    The morphologic changes occurring in apoptosis include compaction and segregation 
of nuclear chromatin, condensation of cytoplasm, the convolution of the nuclear and cell 
outlines, nuclear breakdown into discrete fragments, and surface protuberance forming 
membrane-enclosed apoptotic bodies. The apoptotic bodies are ingested by neighboring 
cells and degraded in lysosomes.17 In chemotherapy, tumor regression and side effects are 
both caused by the enhanced extensive apoptosis induced by chemotherapeutic agents.18 
    The deregulated proliferation and suppressed apoptosis are the hallmarks of cancer. 
Accordingly, two strategies are used for cancer treatment: therapies targeting mitotic 
spindles to block the tumor growth by interfering with mitosis, and therapies inducing 
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extensive apoptosis of tumor cells. However, neither strategy has achieved the goal of 
confining death to cancer cells and allowing the survival of normal cells, because of the 
confusion caused by the similar proliferative features existing in some normal tissues 
such as gut epithelium and bone marrow. In order to reduce the adverse effects on normal 
organs and tissues, further research is still required for a deeper understanding of 
cancer.19 
 
1.2 Microtubules 
Microtubules (MTs), along with actin and intermediate filaments, are the three major 
cytoskeleton components. Cytoskeleton organizes cell contents, connects cells with their 
external environment, and regulates cell motility as well as morphology.20 Among the 
three filamentous proteins, MT is the largest, with the diameter around 24 nm. Actin is 
the smallest type of filament, with the diameter around 7 nm. Intermediate filament, as 
the name implies, is mid-sized, with the diameter around 10 nm.21 
1.2.1 Structure and functions 
MT appears as a hollow tube consisting of α- and β-tubulin subunits. Both tubulin 
monomers are very similar globular proteins. They associate together via non-covalent 
bonding and form heterodimers as building blocks of MT. Tubulin heterodimers string 
together forming long strands called protofilaments. The alternating assembly of α- and 
β-tubulins leads to structural polarity of the linear protofilaments. Normally, 13 parallel 
protofilaments associate side-by-side and form the cylindrical tube.22 The assembled 
tubular structure has one end with the exposure of α-tubulins and the other end with the 
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exposure of β-tubulins. The polarity of MT is defined by denoting the α-tubulin end as 
minus (–) end and the β-tubulin end as plus (+) end. Each tubulin monomer binds to a 
guanosine triphosphate (GTP) molecule. The GTP molecule bound to α-tubulin is non-
exchangeable, while the GTP molecule bound to β-tubulin is exchangeable. The 
polymerization of MT is driven by the hydrolysis of GTP binding to the subunit of β-
tubulin. Only dimers with GTP at the exchangeable site can polymerize. GTP is 
hydrolyzed to guanosine diphosphate (GDP) and the nucleotide becomes non-
exchangeable.23 Another tubulin isoform, γ-tubulin, acts as a template for the correct 
assembly of MT.24 The γ-tubulin ring complex forms a capping protein at the minus end 
to modulate the minus end dynamics.25 (Figure 1.2A) 
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Figure 1.2 Scheme of MT structure and dynamics. (A) The polarized structure of MT 
with linear protofilaments laterally aligned to form a 24 nm wide hollow cylinder. (B) 
The MT polymerizing, paused and depolymerizing phases. (From Conde and Caceres, 
2009)26 This figure is adapted with permission. 
 
    Each tubulin can be divided into three sequential domains: N-terminal domain, 
intermediate domain and C-terminal domain. The N-terminal domain comprises the 
alternation of parallel beta strands (S1-S6) and helices (H1-H5).  The intermediate 
domain comprises five helices (H6-H10) and mixed beta strands (S7-S10). The C-
terminal domain comprises two anti-parallel helices (H11-H12) that cross over the other 
two domains.27  
    The minus end of MT is anchored in MT organizing centers called centrosomes. MTs 
grow from centrosomes to the plasma membrane. MTs compose mitotic spindles, which 
interact with chromosomes and orchestrate the movement of chromosomes.28    
1.2.2 Dynamic behaviors 
The length of MT is constantly changing, with heterodimers constantly adding and 
subtracting at both ends. The addition and subtraction at the minus end are much faster 
than that of the plus end, the unbalanced rate at two ends causes the dynamic change of 
MT length. The event with transition from growing or pausing state to shortening state is 
called catastrophe. On the contrary, the event with opposite transition is called rescue.28 
(Figure 1.2B) 
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    The highly dynamic MT cytoskeletal fibers exhibit two types of non-equilibrium 
dynamic behaviors: treadmilling and dynamic instability.29 Treadmilling refers to no net 
growth of MT because the loss of heterodimers at plus end is balanced by the addition of 
heterodimers at minus end. Tubulin subunits treadmill from plus end to minus end during 
the treadmilling process. Dynamic instability refers to the stochastic switch between the 
growing and the shrinking phase.29 During polymerization of MTs, the addition of dimers 
at plus end is much faster than at minus end. During depolymerization of MTs, the loss of 
dimers at plus end is much faster than at minus end. Also, addition or loss of tubulin 
subunits at plus end is more extensive than that at minus end. Therefore, the dynamicity 
at plus end is much more active than that at minus end.29  
    The dynamics of MT are essential for their functional roles. The dynamic mitotic 
spindles are also among the most important targets for anti-cancer drugs. The principle is 
that MT functions are determined by the dynamics of MT and the dynamics can be 
altered by MT-targeted agents. The mitotic spindles lead the movement of chromosomes 
during mitosis. In order to equally partition the replicated chromosomes and segregate 
them to two daughter cells, mitotic spindles must undergo random assembly and 
disassembly by continuous addition or loss of tubulin subunits.14 Any reagents binding to 
αβ-tubulin heterodimers that block the polymerization or depolymerization of mitotic 
spindles would arrest the cell division.29  
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1.3 Microtubule-targeted agents 
Based on whether the MT-targeted agents promote or prevent polymerization, they can 
be classified into two categories: MT stabilizers and MT destabilizers. Some of the MT-
targeted agents have been already developed into chemotherapeutics for cancer treatment, 
and are called antimitotic drugs. Antimitotic drugs suppress the dynamics of mitotic 
spindles, inhibit mitosis, and induce apoptosis. The binding sites of antimitotic drugs are 
known as vinca, colchicine or taxane site.29 Exceptions also exist. For instance, noscapine 
and estramustine are MT-targeted agents as well, but their binding sites belong to none of 
the three known sites above. These agents belong to a new category, whose binding site 
is called the novel site.30 
1.3.1 Microtubule stabilizers 
The most well-known example of MT stabilizers is paclitaxel or taxol. MT-stabilizing 
agents include those targeting MT at the taxane site, such as docetaxel, discodermolide, 
ixabepilone, cyclostreptin, and eleutherobins. Other stabilizing agents bind MT at the 
novel site, such as laulimalide, peloruside A, epothilones, patupilone, sarcodictyins, 
dictyostatin, rhazinalam, certain steroids and polyisoprenyl benzophenones.30 As the 
name of the category implies, MT stabilizers prevent MT from depolymerizing. MTs 
targeted by stabilizers keep growing, and the dynamic behaviors of treadmilling and 
dynamic instability are dramatically inhibited. The inhibition of MT dynamics, in turn, 
disrupts the functions of mitotic spindles involved in congression and segregation of 
chromosomes, causing the arrest of mitosis and further devastation of cell death resulting 
from apoptosis. The binding site of taxol is located at the interior surface of β-tubulin.31 
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The reason for stimulating polymerization is that the binding of stabilizers causes 
conformational changes of tubulin dimers to strengthen the contacts with neighboring 
subunits.23 In vitro experiments showed that the chromosomes of human cells treated 
with taxol no longer congressed uniformly at the metaphase plate during mitosis, and 
some chromosomes were stuck at the pole. Due to the interference with chromosome 
alignment, cell division was blocked.32 (Figure 1.3A-B) 
1.3.2 Microtubule destabilizers 
The MT destabilizing agents include those targeting MT at the colchicine site and the 
vinca site, respectively, as well as other agents binding MT at the novel site, such as 
estramustine, noscapine, halichondrins and combretastatins.29 The colchicine-site agents 
include colchicine, ombrabulin, 2-methoxyoestradiol and indibulin. Among them, 
colchicine has not yet been used for cancer treatment due to its potent toxicity.33 The 
vinca-site agents encompass cryptophycins and vinca alkaloids, including vinblastine, 
vincristine, vinorelbine, vindesine and vinflunine.29 In contrast with the MT stabilizers, 
the MT destabilizers promote the depolymerization of MTs and cause perturbations on 
the dynamics of treadmilling as well as the random switch between growing and 
shortening states, which also defunctionalizes the mitotic spindles and terminates mitosis. 
The MT-destabilizing agents cause the conformational changes of functional segments to 
weaken the lateral and longitudinal contacts; thus, the structure of αβ-tubulin heterodimer 
is destabilized and MTs tend to depolymerize.34 Unlike the taxol site, the colchicine 
binding site is located at the exterior surface of β-tubulin.35 The binding site of 
vinblastine is located at the interface of the αβ-tubulin heterodimer comprising residues 
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from both α- and β-tubulin.36 In vitro studies showed that the breast cancer MCF-7 cells 
proliferated smoothly and quickly without applying any treatment, however, the MT 
network was damaged and broken into short pieces after adding vinblastine.14 (Figure 
1.3C-D) 
 
Figure 1.3 Confocal microscopy images of cancer cells revealing the drug effects.  
Human osteosarcoma cells at early metaphase in (A) the absence of taxol and (B) the 
presence of 10 nM taxol. MTs are in red, chromosomes are in blue and kinetochores are 
in green. (From Kelling et al., 2003)32 Breast cancer MCF-7 cells (C) without any 
treatment and (D) with vinblastine. MTs are in green and nuclei are in red. (From Stanton 
et al., 2011)14 These figures are adapted with permission. 
 
14 
 
1.4 Carbon nanotubes 
Carbon nanotubes (CNTs) are hollow tubes with diameters in the range of a few 
nanometers and lengths up to hundreds of micrometers. The wall of the tube is made of a 
hexagonal lattice of carbon atoms, similar to the planar graphene layers in graphite. 
CNTs were first discovered by Iijima in the early 1990s.37-38 With extensive studies, 
CNTs have been applied across disciplines in composite materials, microelectronics, 
energy storage, biosensor and cancer treatment, due to their unique electronic, optical and 
chemical properties.39 
1.4.1 Structure  
The carbon atoms in CNT are in sp2 hybridization, they are similar to the carbons in 
graphite. The bonds formed by carbon atoms with sp2 hybridization are stronger than 
those formed with sp3 hybridization, contributing to the considerable strength of CNTs. 
CNTs are classified into two main groups: single-walled CNTs (SWNTs) and multi-
walled CNTs (MWNTs). The formation of SWNTs can be visualized as one graphene 
sheet wrapped into a seamless cylindrical tube and, similarly, the formation of MWNTs 
can be pictured as multiple graphene sheets wrapped into seamless coaxial cylinders. 
According to the method of rolling graphite layers into a tubular structure, CNTs are 
distinguished by chirality as armchair, zigzag and chiral. With a pair of unit vectors (a1, 
a2), the wrapping vector C is defined as C = na1 + ma2, where n and m are two integers. 
The integer pair (n, m) can describe the chirality of CNTs. If n = m, this corresponds to 
the armchair type. If m = 0, this corresponds to the zigzag type. When non-zero n and m 
are not equal, this corresponds to the chiral type of CNTs.40 (Figure 1.4) 
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Figure 1.4 Schematic depiction of CNT formation by wrapping a graphene sheet. The 
tube axis T is shown by the dashed line. (a1, a2) is a pair of unit vectors and n and m are 
two integers to describe the chirality. The wrapping vector C is defined as C = na1 + ma2. 
The solid vector H is perpendicular to the longitudinal axis along the armchair direction. 
The chiral angle φ is the angle between T and H. The chiral tube has a wrapping angle θ 
relative to the longitudinal axis along the zigzag direction. (From Wilder et al., 1998)41 
This figure is adapted with permission. 
 
    The ideally identical hexagonal lattice structure of CNTs does not exist in reality. 
Defects are inevitable during the synthesis process. Approximately, up to 1-3% of carbon 
atoms are oxidized and acidified during the process of synthesis by laser vaporization or 
electric arc discharge techniques and the subsequent purification.42 The defect sites are 
more chemically active than the regular structure and can lead to further 
functionalizations. Some properties of CNTs, such as solubility and dispersity, can be 
improved through chemical functionalization of pristine CNT structures. Two strategies 
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are implemented to functionalize the CNT structure: covalent modification of the CNT 
sidewall or ends, and non-covalent wrapping lipids or polymers on the CNT surface.43 
Oxygen containing groups, such as carboxyl and hydroxyl groups, are formed at some 
defect sites by oxidation reactions in the concentrated acidic environment of mixed nitric 
acid and sulfuric acid under ultrasonic treatment.44 The carboxyl groups introduced by 
acidic oxidation can proceed with further reactions, such as esterification or amidization, 
which in turn provide covalent linkages to a wide range of functional moieties.44 The 
covalent modification transforms the bonding structure from sp2 to sp3 at active sites 
resulting in the partial loss of π-conjugation. Conversely, the non-covalent 
functionalization maximally preserves the original properties of CNTs, and can 
remarkably improve solubility with the aid of hydrophilic groups. For instance, aromatic 
compounds interact with CNT sidewalls by π-π stacking interactions; conjugated 
polymers with aromatic rings can wrap CNT sidewalls through π-π stacking and van der 
Waals interactions.43 
1.4.2 Applications 
The applications of CNTs range from electronics, energy conversion and storage to 
enhanced composite fibers, biosensors and biomedical devices. For example, the large 
surface area of CNTs provides sufficient electrode-electrolyte contact, expedites the 
charge-discharge rates, and decreases resistance for ion transport; therefore, CNTs are 
used as anode materials for preparing light and portable lithium-ion batteries with high 
energy density.45 The low density and promising mechanical properties, such as high 
Young’s modulus and tensile strength of CNTs46, facilitate the usage of CNTs as fillers to 
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manufacture enhanced load-bearing composite fibers.47 The large effective working area 
of SWNT modified glassy carbon electrodes dramatically increases the peak current of 
cyclic voltammogram, after coating annealed SWNT film on glassy carbon electrode 
surface. The nanostructured topology of annealed SWNT surface advances direct electron 
transfer to the adsorbed enzyme and therefore, significantly increases the electroactivity. 
CNT modified electrodes promote electron transfer and provide a new paradigm on the 
design of highly sensitive nanobiosensors to detect biological redox molecules.48 
The functionalization of CNTs by non-covalent coating of amphiphilic molecules, or 
covalently grafting polar functional groups onto the sidewalls creates soluble and 
debundled CNTs in an aqueous environment. Therefore, functionalized CNTs are widely 
used in biomedical areas such as transportation vehicles for therapy or diagnosis.49 
SWNTs, ~400-500 nm in length and 1.2-1.5 nm in diameter, were functionalized with 
poly(ethylene glycol), biotin, tyrosine and alkyl chain, showing an amphiphilic character, 
to deliver doxorubicin (DOX) to cervical cancer derived HeLa cells and non-cancerous 
Chinese Hamster Ovarian (CHO) cells. At the same drug concentration, SWNT-DOX 
achieved a much higher efficacy to kill the two types of cells than free DOX because of 
the enhanced internalization of the drug-SWNT system. HeLa cells expressed much more 
biotin receptors than CHO cells, the receptor-mediated specific transportation of DOX 
loaded on biotinylated SWNTs caused more death to HeLa cells than CHO cells.50    
CNT-based immunosensors have been developed for early cancer diagnosis through 
clinical detection and measurement of cancer biomarkers. The assembled immunosensors 
consisting of SWNT forest platforms attached by enzyme-antibody-nanotube 
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bioconjugates showed enhanced sensitivity and selectivity for the detection of prostate 
specific antigen in calf and human serum samples. Due to high conductivity and surface 
area of SWNT platform along with the catalytic nature of enzyme labels, a low detection 
limit of 4 pg/mL on the prostate carcinoma biomarker by CNT immunosensors was 
achieved, surpassing the detection limit of commercial immunoassay methods.51 More 
biomedical functions of CNTs are emerging, as the electrical, optical and thermal 
properties of CNTs enable the possibility to detect, monitor and cure diseases.52 
 
1.5 Computer modeling 
Computer modeling refers to the computational studies of any system of interest by 
utilizing molecular modeling techniques with the purpose of understanding the structure-
function correlation at the atomic or molecular levels, and predicting the macroscopic 
properties of a system. Quantum mechanics and molecular mechanics are the modeling 
techniques used to study systems ranging from small molecular scale to large 
biomacromolecular scale.  
1.5.1 Molecular Docking 
Molecular docking is a computational technique used to study the molecular recognition 
involved in protein–protein, ligand–protein (small molecule and protein) as well as ligand 
and nucleic acid (small molecule and DNA/RNA) interactions. The origin of such 
interactions is the collective effect of hydrophobic interactions, van der Waals forces, 
hydrogen bonding, and electrostatic forces. The docking problem can be divided into two 
parts: searching and scoring. Searching and scoring are coupled in the docking process: 
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scored decisions are made during the progression of searching. Four widely used docking 
programs are DOCK53-54, FlexX55, GOLD56 and ICM57. Although each software has its 
unique searching and scoring algorithms, they share a mutual algorithmic foundation 
since they are aimed to search for a matchable conformation by taking into account all of 
the possible inter-atomic forces. A decision needs to be made whether to accept or reject 
the detected binding geometry according to criteria set in the scoring function. If accepted, 
a pose is generated; if rejected, a new search will start. The coupled searching and 
scoring step continues to generate all acceptable poses, and all candidate poses are ranked 
based on the scoring function correlated to the binding affinity. Three types of docking 
have been developed in the past: rigid body docking, with both the ligand and the 
receptor rigid; flexible ligand docking, with the ligand flexible but the receptor rigid; 
flexible docking, with both the ligand and the receptor flexible. Due to the limits on 
computational efficiency, flexible ligand docking is the most commonly used method to 
pinpoint the binding sites of small molecules interacting with macromolecules.58 The 
drawback of the rigid receptor in flexible ligand docking is addressed with more 
advanced methods to include the flexibility of both ligand and receptor, which will be 
discussed later. 
    Several factors can affect the accuracy of the predicted binding site and the reliability 
of the scores for ranking docking solutions. One factor is the ligand structure, including 
protonation and tautomeric states. Another factor is the receptor structure in terms of the 
resolution of crystal structures, or the choice of template used for homology modeled 
structures. Apart from the candidate structure of ligand and receptor, receptor flexibility 
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is another key factor in determining the docking output. Despite the frequently used 
pattern of flexible ligand and rigid receptor, receptors are not actually rigid upon ligand 
binding. They most likely undergo conformational changes, such as major side chain 
flexibility and minor backbone displacement.59 The ligand induced conformational 
changes, also known as induced fit, make the contact with ligand or solvent in more 
energetically favorable conformations.60-61 Therefore, the rigid receptor hypothesis could 
lead to inaccurate binding modes and poor docking scores. In order to address challenges 
encountered in the rigid receptor setting, the concept of “soft docking” has been 
introduced to the docking algorithms. Soft docking considers geometric and energetic 
complementarity by allowing small conformational changes62 as well as the idea of side-
chain flexibility by extending the search for more rotameric states of amino acid side 
chains.63 
    The scoring function also plays a dominant role in the fidelity of docking solutions. 
The scoring functions are classified into three categories: knowledge-based, empirical 
and force-field based scoring function.58, 64 Based on the statistical analysis of 
experimentally determined protein-ligand complexes, knowledge-based scoring functions 
are developed by elucidating the rules for stable and unstable atom pair interactions from 
the experimental data. 65 The empirical scoring function adds up the enthalpic and 
entropic interactions with contributing terms of different weight, including van der Waals, 
electrostatic interactions and hydrogen bonding, determined by the regression of 
experimentally measured binding affinities from the training set of protein-ligand 
complexes. The FlexX scoring function belongs to this type.55, 66 The third type of scoring 
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function, based on the force field, is similar to the empirical type by adding up individual 
terms of different types of interactions for the prediction of binding affinity; however, the 
difference lies in the source of the terms: the interaction terms in the force-field based 
scoring function are extracted from the physical and chemical phenomena rather than 
from the experimentally determined binding free energies as in the scenario of the 
empirical scoring function. The scoring function utilized in DOCK belongs to the force-
field based category.67 
    Ligand–protein docking is widely used in rational drug design, for instance, the 
docking of small molecules with therapeutic function to protein or nucleic acid targets. 
Protein–protein docking, on the other hand, advances studies on molecular recognition, 
inhibitor design, cellular pathways, as well as macromolecular interactions and 
assemblies.68 
1.5.2 Molecular dynamics simulations 
Molecular dynamics (MD) simulations are computer simulations of the physical motion 
of particles in a system. The system under study ranges from a single particle to a huge 
system with massive particles, such as a protein macromolecule with hundreds of amino 
acids and tens of thousands of atoms. The movements of particles are determined by the 
Newtonian equations of motion. Solving the interaction potential equations for all of the 
particles in a system is a core part of MD simulations.  
    For particle i in a system with N particles, Fi is the force applied on the particle, ri is 
the coordinate for the particle at the given time t, mi is the mass of particle i, and V is the 
potential function of the system.69 
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    The interacting forces are the negative derivatives of potential functions; 
 𝐹𝑖 = −
𝜕𝑉
𝜕𝑟𝑖
 (Equation 1.1) 
 
    Force is also determined by Newton’s second law; 
 𝐹𝑖 = 𝑚𝑖
𝜕2𝑟𝑖
𝜕𝑡2
 (Equation 1.2) 
 
    The equations for calculating the potential energies and forces along with the 
parameters set for the equations compose a force field. Common force fields used in MD 
simulations include CHARMM70-71, AMBER72-73, GROMOS74-75 and OPLS76. The 
equations applied in a force field are classified into two categories: equations for 
calculating bonded interactions and equations for non-bonded interactions. Bond 
stretching, angle bending and torsions are bonded interactions; van der Waals (vdW) 
forces and Coulomb forces are non-bonded interactions.  
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Figure 1.5 Scheme of bonded interactions. (A) Bond stretching between atom i and j, (B) 
angle bending among atoms i, j and k, and dihedral angles among atoms i, j, k and l in the 
form of (C) proper dihedral as well as (D) improper dihedral.  
 
The potential energy for bond stretching, Vb, is calculated by Hooke’s law (harmonic 
potential): 
 𝑉𝑏(𝑟𝑖𝑗) =
1
2
𝑘𝑖𝑗
𝑏 (𝑟𝑖𝑗 − 𝑏𝑖𝑗)
2
 (Equation 1.3) 
 
    where kbij is the bond stretching constant, rij is the interatomic distance, and bij is the 
reference bond length.69 (Figure 1.5 A) 
The potential energy Va for the vibration among a triplet of atoms i, j and k with the angle 
θijk is also represented by a harmonic potential: 
 𝑉𝑎(𝜃𝑖𝑗𝑘) =
1
2
𝑘𝑖𝑗𝑘
𝜃 (𝜃𝑖𝑗𝑘 − 𝜃𝑖𝑗𝑘
0 )
2
 (Equation 1.4) 
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    where kθijk is the angle bending force constant and θ0ijk is the reference bond angle.69 
(Figure 1.5 B) 
The 4-body dihedral angles include proper dihedrals for non-planar groups and improper 
dihedrals for planar groups. The proper dihedral Vd for a quartet of atoms i, j, k and l with 
the dihedral angle φ between the (i, j, k) and (j, k, l) planes is given by, 
 𝑉𝑑(𝜑𝑖𝑗𝑘𝑙) = 𝑘𝜑(1 + cos(𝑛𝜑 − 𝜑𝑠)) (Equation 1.5) 
 
    where kφ is the rotation barrier, n is multiplicity, and φs is the phase factor.69 (Figure 
1.5 C) 
The improper dihedral, Vid, for a planar structure with the angle ξijkl between the (i, j, k) 
and (j, k, l) planes is calculated by a harmonic potential: 
 𝑉𝑖𝑑(𝜉𝑖𝑗𝑘𝑙) =
1
2
𝑘𝜉(𝜉𝑖𝑗𝑘𝑙 − 𝜉0)
2
 (Equation 1.6) 
 
    where kξ is the bending force constant and ξ0 is the reference bending angle.69 (Figure 
1.5 D) 
The vdW interactions are the combined effects of long-range attractive forces and short-
range repulsive forces. vdW interactions, VLJ, between atoms i and j separated by the 
interatomic distance rij are modeled by the Lennard-Jones (LJ) potential:  
 𝑉𝐿𝐽(𝑟𝑖𝑗) =
𝐶𝑖𝑗
(12)
𝑟𝑖𝑗
12 −
𝐶𝑖𝑗
(6)
𝑟𝑖𝑗
6  
(Equation 1.7) 
 
    where C(12)ij and C
(6)
ij are LJ parameters depending on the pair of atom types. r
–12
ij and 
r–6ij indicate the terms for repulsive and attractive forces, respectively.
69 
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The Coulomb interactions, Vc, between atoms i and j with partial atomic charges qi and qj 
are computed by the electrostatic potential: 
 𝑉𝑐(𝑟𝑖𝑗) =
1
4𝜋𝜀0
𝑞𝑖𝑞𝑗
𝜀𝑟𝑟𝑖𝑗
 (Equation 1.8) 
 
    where ε0 is the vacuum permittivity and εr is the relative dielectric constant.69 
Taking into account the bonded and non-bonded interactions, the potential function V(rN) 
for a N-particle system is defined as below69: 
𝑉(𝑟𝑁) = ∑
1
2
𝑏𝑜𝑛𝑑𝑠
𝑘𝑖𝑗
𝑏 (𝑟𝑖𝑗 − 𝑏𝑖𝑗)
2
 
+ ∑
1
2
𝑎𝑛𝑔𝑙𝑒𝑠
𝑘𝑖𝑗𝑘
𝜃 (𝜃𝑖𝑗𝑘 − 𝜃𝑖𝑗𝑘
0 )
2
 
+ ∑ {𝑘𝜑(1 + cos(𝑛𝜑 − 𝜑𝑠)) +
1
2
𝑘𝜉(𝜉𝑖𝑗𝑘𝑙 − 𝜉0)
2
}
𝑡𝑜𝑟𝑠𝑖𝑜𝑛𝑠
 
+ ∑ ∑ [(
𝐶𝑖𝑗
(12)
𝑟𝑖𝑗
12 −
𝐶𝑖𝑗
(6)
𝑟𝑖𝑗
6 ) +
1
4𝜋𝜀0
𝑞𝑖𝑞𝑗
𝜀𝑟𝑟𝑖𝑗
]
𝑁
𝑗=𝑖+1
𝑁
𝑖=1
 
(Equation 1.9) 
 
    An initial set of coordinates for each particle in a system is required in order to start an 
MD simulation. The coordinates generate a three dimensional (3D) structure for the 
system under study. In the case of proteins, the 3D structure is obtained experimentally 
by X-ray crystallography or nuclear magnetic resonance (NMR), or theoretically by 
homology modeling provided with a known homologous structure. The initial structure is 
refined by energy minimization for the stress relief caused by bond length distortions or 
overlapped non-bonded atoms. Initial velocities are randomly assigned to each particle in 
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the system. The duration of an MD simulation varies from picoseconds to nanoseconds, 
depending on the size (complexity) of the system. In general, the more particles a system 
contains, the longer a simulation will run. After the system reaches equilibrium, the 
simulation can stop. At the post-equilibrium stage, the system shows stabilized 
thermodynamic properties, such as temperature, pressure and energy.77    
    MD simulations can provide continual visualized information on the motion of the 
system; for instance, the folding change of a protein molecule can be thoroughly tracked 
from the MD trajectory. The structural changes sometimes relate to particular functional 
roles, such as the “breathing” conformational changes to open the channel for oxygen and 
carbon monoxide interacting with the buried haem group in haemoglobin.77 MD 
simulations also assist protein crystallography to refine the experimentally determined 
structure. Another important application for MD simulations is to calculate the free-
energy difference between similar systems, which can further elucidate the binding 
affinity of a ligand.77 
 
1.6 Summary 
Targeting the mitotic spindles of microtubules in the midst of cancer cell division has 
been an effective way to conquer the infinite proliferation of tumor cells and will 
continue to be a powerful strategy in the cancer battle. Well-developed computing 
algorithms have advanced computer modeling, making significant contributions to the 
study of interactions between drugs and targets on the atomic scale. The improvement of 
commercially available therapeutics and the discovery of new compounds with enhanced 
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potency, but reduced side effects rely on the combined techniques of computational 
modeling, experimental tests and clinical trials. One of the solutions to seek “smart” 
cancer treatment with high specificity and selectivity relies on the innovations of drug 
delivery systems, considering the advantages of customizable carbon nanotubes as 
carriers for drugs and recognizing moieties. Beyond the resolution of experimentally 
determined three dimensional structures of macromolecules, molecular dynamics 
simulations based on currently available experimental data are able to dig accurate 
conformational details in depth assisting the design of drugs and drug delivery systems.78 
    My thesis elaborates on two aspects relevant to cancer research in the following two 
chapters: first, the effects of one of the commonly used anti-cancer drugs on the tubulin 
dimer structure in contrast with the comparable influence of the low temperature; second, 
the non-covalent interactions between the drug and carbon nanotube based carriers under 
different conditions. Following the two main chapters of the work performed during the 
master’s degree program, the concluding chapter summarizes the entire work and 
provides future perspectives.  
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CHAPTER 2  
 
Drug Binding Site at Tubulin 
Heterodimer and Dimer 
Deploymerization* 
2.1 Introduction 
Microtubules (MTs) are biopolymers comprising 13 protofilaments, each of which is 
built of heterodimer α- and β-tubulin subunits. The monomeric subunits are assembled in 
a head-to-tail alternating layout to form the protofilaments, arranged side-by-side and 
parallel to the MT longitudinal axis. As the polymerization proceeds, thirteen 
protofilaments grow spirally and gradually to form a hollow cylinder-like structure, 
which is the typical appearance of MTs.1-2 
    The polymerization or assembly of MTs refers to the incorporation of new αβ-tubulin 
subunits at MT tips, which corresponds to the elongation or growth state. The 
depolymerization or disassembly of MTs refers to the detachment of αβ-tubulin subunits 
at MT ends, which corresponds to its shortening or shrinkage status. The dynamic 
                                                 
* This chapter was modified from “Microtubules dual chemo and thermo-responsive depolymerization” Li, 
Z. & Alisaraie, L., Proteins: Structure, Function, and Bioinformatics 2015, 83, 970-981. Used with 
permission.  
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variability of MT structure, i.e., random transitions between assembly and disassembly 
states, is essential for the cellular functions of MTs.3 For instance, kinetochores in the 
centromere region of chromosomes bind to spindle MTs during mitosis, and mitotic 
spindles control the movement, alignment and segregation of chromosomes throughout 
the assembly and disassembly of MTs, coping with each phase in the process of cell 
division.4 The successful process of mitosis strongly depends on high MT dynamicity, 
since any misalignment or replication error of chromosomes can terminate mitosis and 
eventually lead to mitotic checkpoint-induced apoptosis.5 However, the important 
dynamics of spindle MTs can be suppressed by some small molecules binding at different 
sites of MT. The MT-targeted compounds are usually anti-mitotic drugs because they are 
capable of slowing-down or blocking mitosis, inhibiting fast proliferation of cancer cells 
and killing tumor cells. Anti-mitotic agents can be classified into two main groups: MT-
stabilizing and MT-destabilizing agents. The MT-stabilizers, such as taxanes and 
eleutherobins, stimulate MT polymerization. The MT-destabilizers, including colchicine, 
vinca alkaloids such as vincristine and vinblastine, by contrast, inhibit MT 
polymerization.6-8 
    Vincaleukoblastine, commonly known as vinblastine (VLB, C46H58N4O9), is a vinca 
alkaloid derived from the periwinkle plant Catharanthus roseus. It is an indole rich 
alkaloid comprising catharanthine and vindoline. The World Health Organization (WHO) 
has listed VLB as one of the most essential medications needed in the health care system 
because of its powerful efficacy for treatment of Hodgkin's lymphoma, non-small cell 
lung cancer, breast cancer, head, neck and testicular cancer types.9 VLB has been shown 
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to inhibit the dynamics of growing and shortening at MT plus ends when used at low 
concentration and hinder MT polymerization at high concentration. The first crystal 
structure of VLB-tubulin complex was solved by Gigant et al.,10 where the VLB binding 
site was identified at the inter-dimer interface of αβ-tubulin heterodimers. Apart from 
MT-targeted drugs, several other factors, including microtubule-associated proteins 
(MAPs), temperature, hydrolysis of guanosine triphosphate (GTP) and critical 
concentration of free tubulins, have been suggested to be crucial in regulating the 
dynamics of MT polymerization and depolymerization.11-12 
    Temperature, a key factor in controlling the switch between growth and shrinkage of 
MTs, can be used to tune the MTs/tubulins conversion in vitro. Early studies showed 
cold-induced disassembly by monitoring the change of turbidity, polymer weight and 
length, when a polymerized MT solution at 303 K was rapidly cooled down to 278 K. A 
conclusion that depolymerization proceeded by the consecutive loss of subunits at MT-
ends was drawn based on the significant decrease of the optical density, polymer weight 
and length.13-14 While conformational changes of tubulins seem to play a central role in 
MT assembly/disassembly processes,15  no explicit study has yet been reported on 
associating the drug-induced and low temperature-induced disassembly mechanism with 
structural variations of MT-heterodimers at the atomic level. The study presented in this 
chapter examines this importance and investigates induced changes on the structural 
conformation of MT imposed by both VLB binding, and reduction of temperature to 277 
K as opposed to room temperature of 300 K.  
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    Another widely used anticancer drug, doxorubicin (DOX), causes DNA damage to 
tumor cells but has not yet been further explored in terms of the possible binding site and 
mechanism of action on MTs at an atomistic level. In fact, the positive effects of DOX on 
the structural damage and the assembly inhibition of MTs16 as well as the reorganization 
of tubulins17 have been reported. Fromes et al. investigated the interference of fluoro-
DOX on tubulin polymerization and pointed out that a possible site for fluoro-DOX 
binding to MT was related to the MAP binding site.18 The sister drug of DOX in the 
anthracycline family, daunomycin, was reported to interact with tubulin heterodimers 
through H bonding and electrostatic force.19 However, neither explicit experimental 
evidence nor computational studies have reported detailed DOX interactions with MT. 
The work presented in this chapter also explores possible binding sites for DOX targeting 
MT based on a binding pocket finder followed by a refined localization. 
 
2.2 Materials and Methods 
2.2.1 In silico experimental setup 
The αβ-tubulin heterodimer was retrieved from the Protein Data Bank (PDB)20 with the 
access code of 1JFF21. The missing residues sequenced as 1, 35-60, 440-451 of α-tubulin 
and 1, 438-445 of β-tubulin were constructed and merged with the X-ray structure of the 
protein in 1JFF as described elsewhere22 using the complete amino acid sequences of α-
tubulin with 451 residues and β-tubulin with 445 residues and respective UniProt23 access 
code of Q2HJ86 (Bovine) and P02554 (Pig).  
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    DOX was extracted from 2DR6 in PDB.24 The grid-based HECOMi finder, a web 
server called Ghecom,25 was used to predict the possible binding sites of DOX interacting 
with αβ-tubulin heterodimers. Through simultaneous calculations of shallowness and 
depth of probes with multiple sizes binding to the protein surface, Ghecom applies the 
mathematical morphology idea to detect pockets of ligands, and shows greater 
advantages than other binding-site searching servers in terms of efficiency and accuracy 
on binding pocket predictions.25 
    The FlexX package (version 2.1.3)26-28 was utilized as the docking tool to search for the 
most energetically favorable binding conformation of VLB in MT and calculate its total 
binding score to be used as the starting structure for MD simulations. Polar and non-polar 
hydrogen atoms were assigned to VLB, while the whole molecule had a net charge of (+1) 
due to protonation under physiological conditions. Hence, the nitrogen at  position 6’ in 
the catharanthine sub-structure of VLB was set as protonated under physiological 
conditions.29 (Figure 2.1) 
 
Figure 2.1 Chemical structure of mono-protonated VLB. 
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    FlexX applies an incremental construction algorithm as it selects a fragment of VLB as 
the base-fragment to place into the designated binding site and adds the remaining 
fragments of the molecule to connect with the base in an incremental fashion. The output 
docking solutions of VLB are ranked according to their corresponding total binding 
energies (∆Gbinding) calculated based on the Böhm scoring function30. 
2.2.2 Molecular dynamics (MD) simulations 
In order to study the individual effects of VLB and low temperature on tubulin 
heterodimer structure in dynamic mode, MD simulations were performed after docking 
VLB into the αβ-tubulin heterodimer. The starting point structure of the liganded tubulin 
heterodimer for MD simulations was the heterodimer with VLB docked by FlexX. The 
starting point structure of the unliganded tubulin heterodimer for MD simulations was the 
heterodimer with VLB removed from the liganded heterodimer. The topology of mono-
protonated VLB was generated by Automated Topology Builder (ATB, version 2.0)31-32 
based on Gromos96 force field 53A633 followed by a minimization using the Hartree-
Fock/STO-3G basis-set. MD simulations were implemented by utilizing the Gromacs 
package (version 4.5.5)34-35, with the force field of Gromos96 53A6. 
    The bonded interactions, including bond stretching, valence angle bending and bond 
rotation, were modeled based on specific functions; the non-bonded interactions 
including van der Waals and electrostatic interactions were modeled by the Lennard-
Jones potential and electrostatic potential functions, respectively.33 A cut-off distance of 
1.4 nm was assigned for both the Lennard-Jones and electrostatic interactions. The 
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calculation of electrostatic interactions contributing to energies and forces was carried out 
based on the Particle Mesh Ewald algorithm36. The LINear Constraint Solver (LINCS) 
algorithm37 was applied to constrain all bond lengths including those involved in 
hydrogen bonding. The time constant for pressure coupling was set to 1.0 ps, with 
compressibility set as 4.5e–5 bar–1. The temperature was set to either 277 K or 300 K 
with a temperature coupling of 0.1 ps.  
    Each simulated system was first energy minimized using the steepest descent 
algorithm followed by a 100 ps all-bonds position restraint. The harmonic constraints 
were gradually released during MD simulations. The simulations of three systems 
converged before 70 ns and proceeded to additional steps until 115 ns. When the first 
round of simulations for the three systems was completed, a second round of simulations 
was performed for the sake of validation and improvement of the accuracy of predictions. 
The velocities assigned to the energy minimized structure were set differently at random; 
all other settings of the second round simulations were identical to the first round. The 
results discussed below were based on the dynamic changes observed in both the first and 
second rounds of simulations. The calculations were performed on WestGrid high 
performance computer clusters of Compute Canada.38 
 
2.3 Results and Discussions 
2.3.1 DOX binding site prediction by Ghecom and FlexX 
The possible binding sites predicted by Ghecom were ranked into three areas in 
ascending order: grid 1, grid 2 and grid 3. Part of grid 1 also overlapped with the binding 
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site of VLB in the crystal structure of 4EB639. Central residues at each predicted spot 
were used to guide the docking of DOX. The radius around the central residues was set to 
10 Å. Amino acids within this radius were selected to form the binding site. The central 
residues represent the center of the estimated site region, the envelope of which encloses 
the binding site.40 Because of the spread area of grid 1, grid 1 was further divided into 
two areas: one at the top of grid 1, with central residues Ala12, Pro173 and Tyr224 
surrounded by H1, T5 loop, H5, H6 and H7 of α-tubulin; the other at the bottom of grid 1, 
with central residues Ala247 surrounded by T7 loop of α-tubulin and Pro70 surrounded 
by T2 loop of β-tubulin. The central residues of grid 2 were Gly244 and Thr351, which 
were surrounded by T7 loop and S9 strand of β-tubulin. The central residues of grid 3 
were Lys164 and Leu252 surrounded by H3-S4 loop, H4-S5 loop and H8 of α-tubulin, as 
well as Ala102 surrounded by T3 loop and H11-H12 loop of β-tubulin. (Figure 2.2 A-B)  
 
Figure 2.2 DOX binding site prediction. α-tubulin is in yellow and β-tubulin is in green. 
(A) Binding area predicted by Ghecom. Grid 1, the highest ranked cluster, is in cyan. 
Grid 2 is in magenta, Grid 3 is in red. (B) The positions of the central residues are shown 
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in surface mode. For comparison, VLB in the crystal structure of 4EB6 is shown in stick 
mode.  (C) The top ranked docking pose of DOX.  
 
    Five sets of docking experiments were performed based on the binding sites predicted 
by Ghecom. Grid 2, with the lowest binding free energy, was the most favorable binding 
site for DOX. The bind pocket refined further by FlexX was located at the edge of β-
tubulin surrounded by H1-S2 loop, T7 loop, and S9-S10 loop. (Table 2.1 & Figure 2.2 C) 
Table 2.1 ∆Gbinding of the DOX docking experiments. 
 1 2 3 4 5 
Center of 
prediction 
Grid 1 top  
Grid 1 
bottom 
Grid 2 Grid 3 
VLB 
binding site 
∆Gbinding (kJ/mol) -26.01 -24.66 -29.73 -23.09 -25.61 
 
    The binding site of the derivative of DOX, fluoro-doxorubicin, was related to the 
binding sites of MAPs.18 Littauer et al. reported that residue 434-440 on β-tubulin was 
crucial for MAPs interacting with tubulins.41 However, the binding site which was 
predicted by Ghecom and further assessed using FlexX, was not close to the carboxyl-
terminal of β-tubulin. This inconsistency might be due to the different interactions of 
DOX and fluoro-DOX with MT, as well as  the incomplete sequence of β-tubulin in 
Littaurer’s study41.  
2.3.2 VLB bound αβ-tubulin heterodimer 
To benefit from both available crystal structures of tubulin, the uniprot sequence 
identities as well as tertiary structures of 1JFF21 and 4EB639 were compared. As a result, 
five residues in α-tubulin and six residues in β-tubulin of 4EB6 were found non-identical 
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to the counterparts of 1JFF. However, these residues, in either the α- or β-subunit, were 
far from the VLB binding site, such that the closest non-identical residue was ~22 Å 
away from atom C18’ of VLB in 4EB6. This indicates that the VLB surrounding 
environment in 1JFF is identical to the VLB binding site in 4EB6. As described by 
Ranaivoson et al. the crystal structure of the tubulin was molded in 4EB6, and the ligand 
location and its coordination were manually corrected to match the electron density 
map.39 Considering the fact that VLB has a complex chemical structure, and the 
resolution of the X-ray diffraction data “R” for solving VLB-tubulin in 4EB6 is 3.47 Å, 
these factors could affect the accuracy of the observed VLB conformational pose in the 
process of solving the VLB density map and the precise identification of its absolute 
conformational pose. Moreover, due to the technical limitation in crystallography, 
hydrogen atoms are not detected. Hence they are not included in the solved structure of 
VLB-tubulin. As a result, protonation states of amino acids and the ligand are not 
assigned to the solved structure. To address these issues concerning the conformation of 
the protonated VLB and identify the ligand coordination more accurately than manually 
placing the ligand in the crystal structure, the most energetically favorable conformation 
of VLB in the bound state was searched using docking. (Figure 2.3)  
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Figure 2.3 VLB binding site. (A) Tubulin heterodimer from 1JFF (α-tubulin yellow, β-
tubulin green) superimposed on the VLB-bound tubulin tetramer structure in 4EB6 (α-
tubulin red, β-tubulin blue). Residues interacting with VLB in (B) α-tubulin and (C) β-
tubulin. VLB in gray stick, hydrogen bonds in cyan dashed line. 
 
    Among the top 10 docking solutions, the first ranked and sixth ranked were found 
close to the crystallographic geometry of VLB by the smallest root mean square deviation 
(RMSD) of ~6 Å. The vindoline part of the two docking geometries were overlapping, 
the only difference was the orientation of a nine-membered ring where the protonated N 
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was located. The ∆Gbinding of the first ranked docking solution was calculated to be -8.08 
kJ/mol, which was much lower than the sixth ranked solution. Therefore, the geometry of 
the first ranked docking solution was chosen as the starting structure for the ligand. 
(Appendix A Table A1 & Figure A1)  
    This binding conformation of VLB is linked to 8 amino acids from α-tubulin and 4 
amino acids from β-tubulin in the binding site. Phe351 and Val353 (strand S9) of α-
tubulin along with Ser176 (loop T5) and Tyr208 (helix H6) of β-tubulin interact with 
VLB through hydrogen bonding, where the hydroxyl oxygen on the side chain of Ser176 
forms a hydrogen bond with the hydrogen atom of the protonated nitrogen 6’ at a 
distance of 2.4 Å. Val353, Ser176, and Tyr208 interact with VLB via hydrophobic 
interactions, along with Ala247, Leu248 and Asn249 (loop T7), Pro325 and Asn329 
(helix H10), Lys352 (strand S9) of α-tubulin plus Lys174 (loop T5)  and Pro220 (the loop 
between H6 and H7) of β-tubulin. (Table 2.2 & Figure 2.3B-C) 
Table 2.2 The amino acids compose the interacting network of VLB in the first ranked 
docking solution. 
Subunit Binding site 
α-tubulin Ala247 Leu248 Asn249 Pro325 Asn329 Phe351 Lys352 Val353 
β-tubulin Lys174 Ser176 Tyr208 Pro220     
 
2.3.3 MD simulation analysis 
The RMSD of the protein backbone of the unliganded tubulin heterodimer at 300 K and 
277 K, as well as the liganded tubulin heterodimer at 300 K were monitored for the three 
individual MD simulated experiments within a 115 ns MD trajectory. Each system 
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converged at a different time step because each had a different path on the energy surface 
and each simulation was performed independently. For instance, the liganded system was 
converged (stabilized) at approximately 35 ns, roughly 35 ns earlier than the convergence 
of the unliganded structures under temperatures of 300 K and 277 K nearly at 70 ns. Thus, 
the frames from 70 to 115 ns of the trajectories were analyzed throughout the presented 
work. (Figure 2.4) 
 
Figure 2.4 The RMSD plots of the unliganded heterodimer at 300 K (black), 277 K (red) 
and the liganded heterodimer at 300 K (blue) within 115 ns of MD simulations. 
2.3.4 VLB-induced conformational changes 
When a ligand binds to a protein, it causes the binding site to change its shape. This is 
known as induced fit that affects the shape, folding, and activity of the targeted protein.42-
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44 The induced fit occurred as a result of VLB binding. For instance, H10 (α325-331) 
occupied a portion of the binding site in the absence of VLB. However, it shifted away 
from VLB and partially unfolds to a loop (residues 325-327) in the presence of VLB, due 
to the expanding of the binding site space. (Figure 2.5A) 
 
Figure 2.5 Main conformational changes of the liganded heterodimer compared to the 
unliganded heterodimer at 300 K. Both structures are taken from the 105 ns frames of the 
two separate experiments. The liganded (A) α-tubulin and (B) β-tubulin (blue) are 
superimposed on the corresponding unliganded tubulins (black). Residues interacting 
with VLB (cyan ball-and-stick). The inset at (B) shows a close-up of the interacting 
residues of T5 and H6. 
 
    The repositioning and folding changes of H10 are mainly due to the contribution of 
Val328 in the VLB-tubulin interaction. Furthermore, S9 in the liganded α tubulin 
extended three residues, from α352-356 to α351-358, and moved ~1.7 Å toward VLB as 
compared to the unliganded state. The interaction of Phe351 with VLB facilitated the 
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extension of the S9 strand length. H3 and H11, located away from the binding site, both 
shrank and became shorter than their unliganded counterparts as a result of the partial 
unfolding to a simple coil. Particularly noteworthy is a newly formed helix which 
consists of residues α252-259 at the T7 loop. Helicity plot shows that the newly formed 
helix exists for as long as ~65% of the entire simulation time. (Appendix A Figure A2) 
    Conformational changes are also seen in β-tubulin. In the presence of VLB, H6 shifted 
~3.5 Å away from its unliganded pose, increasing the volume of the VLB binding site. 
Meanwhile, Asn204, Glu205 and Tyr208 at H6 developed interactions with VLB. H7 
shifted ~1.8 Å toward VLB and contributed Asn226 to the interaction network. Residues 
β181-186 of H5 were unfolded to a loop along with T5 shifting toward VLB, such that 
Ser172, Lys174, Val175 and Ser176 on the loop established interactions with VLB via 
hydrophobic interactions. This apparently caused unfolding of the adjacent H5. The loop 
H1-S2 (residues 45-47 and 51-53) was located away from VLB binding site but changed 
to a β-hairpin. This flexible loop is effective in the longitudinal interaction and 
stabilization of MT, hence the diminishing conformational freedom through the partial 
conversion of the loop to a β-sheet could have a destabilization effect. (Figure 2.5B & 
Appendix A Figure A3) 
    Water molecules have shown an important role in stabilizing VLB through the water-
mediated hydrogen bonds. The H-bonding network at the 110 ns frame of the liganded 
system started with Gln15 of H1in β-tubulin, extended via 7 water molecules, and ended 
with Val353 of S9 in α-tubulin. VLB formed two hydrogen bonds with water molecules: 
one occurred at the hydrogen atom on protonated N6’ at the catharanthin moiety, and the 
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other was at the carbonyl oxygen of the ester group at C3 in the vindoline sub-structure of 
VLB. At the same carbonyl oxygen, VLB also formed a hydrogen bond with Val353. 
Water molecules built a link between β-tubulin, VLB and α-tubulin, and enhanced the 
drug-receptor interactions through H-bonding network. Therefore, both water mediated 
H-bonding and the hydrophobic interactions between the drug and the tubulin 
heterodimer, contribute to the folding alterations and relocations of the segments around 
the binding site as seen in S9 moving toward VLB. 
2.3.5 Cold-induced conformational changes 
As compared to the unliganded tubulin heterodimer at 300 K, five major variations were 
found in α-tubulin and four major variations in β-tubulin under the low temperature 
condition of 277 K. In α-tubulin, H5 (185-197) was unfolded to a loop whereas H3, H10 
and H11 were elongated, covering residues 106-111, 323-337 and 398-401, respectively. 
(Figure 2.6A & Appendix A Figure A4) 
    Under the aforementioned condition in β-tubulin, the H3 shrank from residues 110-125 
down to residues 110-122. H5 was shortened from residues 180-193 down to residues 
184-190. H7 was shortened from residues 222-241 to residues 222-233. A β-hairpin was 
also created by H1-S2 loop (residues 34-36, 41-43). (Figure 2.6B & Appendix A Figure 
A5)  
    A newly formed helix (252-259) was also found at the same region of the loop T7 as in 
the liganded system. The helix was formed in both experiments: VLB binding and low 
temperature. The helix existed for ~70% of the simulation time in the unliganded and low 
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temperature systems at 277 K, which lasted a shorter period of time than that of the 
liganded system. (Appendix A Figure A2 & A4) 
 
Figure 2.6 Major structural changes of the unliganded heterodimer at different 
temperatures. (A) α-tubulin and (B) β-tubulin at 277 K (red) superimposed on the 
equivalent unliganded subunits at 300 K (black) at 105 ns frame of MD trajectory. 
  
    VLB and low temperature both triggered the formation of a new helix at the same 
region of T7 loop; the elongation of H10 in α-tubulin. They also caused the formation of 
a β-hairpin at H1-S2 loop and the partial unfolding of H5 in β-tubulin. However, H3 and 
H11 of α-tubulin were partially unfolded in the VLB-bound system but their folding was 
enhanced in the low temperature system.  
    The region of α-T7-H8 along with β-T3 and T5 loops in MT may be coordinated by 
the exchangeable nucleotide site (E-site) and behave like a cohesive structural unit across 
the longitudinal interface.22, 44 The interaction of β-T5 with VLB and the partial 
conversion of α-T7 to a helix containing the key residue Glu254 for GTPase activity,10, 45 
as shown by MD simulations at both the drug-binding and low temperature scenarios, 
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imply that low temperature and VLB could potentially affect the contact of E-site 
nucleotide, and consequently slow down the hydrolysis or exchange rate of E-site 
nucleotide suppressing MT polymerization.46 
    A previous study has shown that the H1-S2 loop functionalized the lateral contacts of 
protofilaments and H3 involved in the longitudinal contacts of heterodimers. H10 
participated in both the longitudinal and lateral contacts and T7 involved the nucleotide 
region interaction.47 For example, the transformation of H1-S2 loop to a β-hairpin 
stimulated by VLB and low temperature causes the loss of structural flexibility and 
further leads to MT depolymerization by weakening lateral contacts. Correlating with the 
aforementioned data47, the structural variations affecting the longitudinal and lateral 
contacts through the H1-S2 loop, H3, and H10 imposed by both the drug and low 
temperature in MD simulations demonstrate their potential depolymerization effects. 
2.3.6 Solvent accessible surface area of heterodimer 
The solvent accessible surface area (SASA) is defined as the total surface area of an atom 
subtracting the contact area with its neighboring atoms, where the more contacts with 
surrounding atoms, the less the SASA.48 Because the unliganded and liganded tubulins 
are immersed in water, one tubulin heterodimer with less water accessible surface area 
corresponds to more interatomic interactions. To minimize the effects of highly 
fluctuating simple coils on SASA plots, the C-terminal extended loop of α-tubulin (437-
451) and β-tubulin (426-445) were omitted for SASA calculations. The SASA for the rest 
of α- and β-tubulin shows α-tubulin is more water-exposed than β-tubulin for each system. 
(Figure 2.7)  
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Figure 2.7 SASA of α- and β-tubulin in three systems varying over the 115 ns simulation 
time. 
 
    Furthermore, there is higher percentage of helically folded segments in β-tubulin 
versus α-tubulin. For instance, a longer H12 is seen in β-tubulin than in α-tubulin for all 
three systems. This is revealed by the helicity plot over the entire simulation time.  
(Figure 2.8A) 
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Figure 2.8 Helicity plots, (A) H12 in α- and β-tubulin, (B) H5 in α-tubulin. 
 
    The average SASA values were estimated after the convergence of each system. For 
the unliganded heterodimer at 300 K, the average SASA of the α-tubulin and β-tubulin 
were ~104 ± 2 nm2 and ~97 ± 1 nm2, respectively. For the unliganded heterodimer at 277 
K, the average SASA of its α- and β-tubulin were ~109 ± 1 nm2 and ~99 ± 1 nm2, 
respectively. The α- and β-tubulin of the unliganded system at 277 K are more accessible 
to water than those at 300 K by ~5 nm2 and ~2 nm2, respectively. For the liganded 
heterodimer at 300 K, the average SASA of its α- and β-tubulin were ~108 ± 2 nm2 and 
~99 ± 1 nm2, respectively. The α- and β-tubulin of the liganded system at 300 K are more 
water-exposed than those of the unliganded system at 300 K by ~4 nm2 and ~2 nm2, 
respectively. (Figure 2.7) 
    The SASA plots demonstrate that the overall comparable destabilization effect to the 
α- and β-tubulin is caused by low temperature and VLB, because the average SASA 
value of each subunit is greater than the corresponding subunit of the unliganded system 
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at 300 K. For instance, the destabilization of α-H5 occurred in the low temperature and 
liganded systems over the course of simulation time. (Figure 2.8B)  
    While some segments in scattered areas were stabilized, such as the elongation of α-H3, 
H10 and H11 in the low temperature system, α-H10 and S9 in the liganded system and 
the newly formed helix (α252-258) at T7 loop as well as the β-hairpin at β H1-S2 loop in 
both the low temperature and liganded systems, the dominant effect attributed to low 
temperature and VLB is to reduce the stability of the whole structure when taking into 
account all the changes in the secondary structure.  
    The SASA plots of the H1-S2 loop of α- and β-subunit for the three systems exhibited 
an average water accessible area of nearly 25 nm2 after the corresponding convergence 
time of each system. The SASA plots were calculated for 40 residues of H1-S2 loops in 
each subunit. In α- and β-subunits, 21 and 24 residues respectively were polar resulting in 
the relatively large SASA. (Appendix A Figure A6) 
2.3.7 Curvature change of heterodimer 
H7 is a central helix in α- and β-tubulin that orients along the longitudinal axis of MT 
protofilaments. It translates accordingly during the reversible straight to bent 
conformational conversion under the disassembly or assembly process.49-50 Therefore, H7 
helices in monomers were chosen for monitoring the curvature change of heterodimers 
under different conditions. The reference structure for the comparison was the crystal 
structure of the tubulin with VLB in 4EB639, because the bent conformation of a tubulin 
complex with the stathmin-like domain of the RB3 protein (SLD-RB3) was similar to the 
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curved protofilaments, which caused a loss of lateral contacts and subsequent 
disassembly.49 
    Heterodimer structures were taken from the 70, 90, 100, and 110 ns frames of the three 
MD simulation systems, in order to assess the trend of conformational changes as 
compared to the VLB-bound dimer in the crystal structure as the reference structure. 
Keeping the β-subunit of the VLB-bound 4EB6 fixed, and superimposing the β-H7 of 
MD simulated structures on the β-H7 in 4EB6, the orientation of α-H7 exhibited the 
curvature deviating from the observed bent conformation in the crystal structure. (Figure 
2.9) 
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Figure 2.9 The curvature of αβ-tubulin heterodimer represented by H7 orientation. The 
unliganded heterodimer at (A) 300 K and (B) 277 K as well as (C) the liganded 
heterodimer at 300 K. The angles indicate the average deviation of heterodimers shifting 
from the curved conformation in the crystal structure. The inset scheme at (A) describes a 
bent to straight conversion. The conformation of H1-S2 loops in the unliganded 
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heterodimer at (D) 300 K, (E) 277 K and in (F) the liganded heterodimer at 300 K.  For 
clarity, only H7 helices are highlighted in cartoon mode. 
 
    The unliganded α-H7 at 300 K was ~12-25° shifted away from the reference line 
passing through the H7 helices in the crystal structure, while the unliganded α-H7 at 277 
K was ~15-28° shifted away from the reference line. The liganded α-H7 of 300 K 
oriented in a similar way to the α-H7 in the crystal structure. It was shifted ~0-4° away 
from the reference line and nearly parallel to the orientation of that in the crystal structure.  
    The conformation and orientation of the monomers in the starting structure, obtained 
from the position restraint step of the calculations, were similar in all three systems. For 
instance, the orientation of H7 pair in the starting structure exhibited the same bent 
structural posture as in 4EB639. The unliganded systems at both 277 K and 300 K showed 
significant deviations from the curved conformation in the crystal structure during the 
course of simulation time, indicating the bent to straight conformation conversion in the 
absence of the drug. However, the liganded system at 300 K maintained similar curved 
conformation to the crystal structure during the MD simulation. Although the low 
temperature can cause changing the curvature of the heterodimer structure, it has less 
effect on bending than that of the drug due to the direct interactions between the drug and 
the β-H7. These observations correlate with the results of the second MD trajectories for 
each of the aforementioned experimental conditions. Compared with the first round 
trajectories, in the second set of experiments, the same frames exhibited stronger effect of 
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drug on bending the structure, more than shown in the X-ray structure. (Figure 2.6B, 
Figure 2.9 & Appendix A Figure A7) 
    Several tubulin segments have been reported to play vital roles in establishing the 
lateral contacts, including the loop H1-S2, H2-S3, H4-T5 and the M loop (272-288).47 
According to our MD simulation results, the H1-S2 loop (residues 24-63) showed 
noticeable conformational changes. For the unliganded system at 300 K, no significant 
change occurred on the H1-S2 loop in both α- and β-subunit.  However, the H1-S2 loop 
in the β-subunit converted to a β-hairpin at frame 70 and 90 ns at 277 K. For the liganded 
system at 300 K, no significant change occurred on the H1-S2 loop in α-subunit, whereas 
the H1-S2 loops of β-subunit altered to β-hairpins at 70, 90, 100, and 110 ns time frames. 
(Figure 2.9D-F) 
    The curvature of protofilaments accompanied by the loss of lateral interactions leads to 
MT disassembly.49 The loss of lateral contacts can be seen from the change of H1-S2 
loops into β-hairpins, identified in β-subunit of both the unliganded and liganded systems 
at low temperature. This means β-subunit is more sensitive than α-subunit in responding 
to low temperature and the drug binding. Since the conversion of the H1-S2 loop to a β-
hairpin in the liganded system is more prevalent than that in the low temperature system, 
we may infer that VLB presumably has a stronger effect than low temperature on causing 
the loss of lateral contacts established by the H1-S2 loop in β-subunit. 
2.3.8 Electrostatic potential map at the interface 
The distribution of electrostatic potential map at the interdimeric interface reflects the 
strength of longitudinal contacts contributed by electrostatic forces. At the heterodimer 
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interface region of the unliganded heterodimers at 300 K, a groove was observed with 
higher accumulation of positively charged residues inside and surrounded by negatively 
charged residues. At the equivalent region of the unliganded heterodimer under low 
temperature, a groove was seen with less accumulation of positively charged residues, 
which was surrounded by a dense negatively charged surface. (Figure 2.10A-D)  
    The electrostatic forces among oppositely charged residues in the groove at 300 K 
occurred among amino acids, including Lys103, Glu108, Glu401 in β-subunit, and Arg2, 
Lys163-164, Arg264 in α-subunit. (Figure 2.10E)  
    The repulsive forces in the groove dominated by negatively charged residues at the 
interface of the heterodimer at 277 K occurred between Glu196 in α-subunit and Glu401, 
Trp101, Trp397 as well as Tyr398 in β-subunit. Thus, the electrostatic repulsion in the 
unliganded system at 277 K is larger than in the unliganded system at 300 K based on the 
density, arrangement and orientation of negatively charged residues. (Figure 2.10A-E) 
    The electrostatic attraction as well as repulsive forces occurring among charged 
residues of α- and β-subunits influence the geometry, shape and size of the groove. 
Among these charged residues were βGlu108- αArg2, βGlu401- αLys163, and αGlu196- 
βGlu401. (Figure 2.10E) 
    The distances between centers of mass (DCOMs) of charged amino acids were 
relatively stable, consequently, the size, shape and distribution of the electrostatic surface 
remained relatively steady throughout the 115 ns simulation time. (Appendix A Figure 
A8 A–C) 
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    VLB binding also affects the distribution of the electrostatic potential map of the 
binding site. (Figure 2.10F-I)  
    In the absence of VLB, the two aspartate residues of β-Asp209 in H6 and α-Asp327 in 
H10 were located 4.9 Å apart from each other, that contribute to the negatively charged 
region around the pocket. They were surrounded by the positively charged β-Arg213, 
Lys297 and α-Lys336. (Figure 2.10J)  
    Residues βAsp209 and βAsp304 were close to αLys326. The surrounded positively 
charged residues of the site, including βLys174, βArg213, βLys216, and αLys326, 
contributed to repulsive forces between the two subunits. 
    In the presence of VLB, β-Asp209 and α-Asp327 were separated by 14 Å away 
because the possessing helices, β-H6 and α-H10, shifted away from the drug, providing 
additional space for its binding. Since they were negatively charged, these displacements 
resulted in reducing the distribution of the negative electrostatic surface at the center of 
the binding site. 
    In the VLB-bound system, the N-terminal end of H10 unfolded to a loop, shifting 
Lys326 away from the two aspartate residues. The displacement of the charged residues 
altered the distribution of the map, as the DCOMs changed among the residues. This 
occurred, for instance, in the pair of βAsp209-αLys326 for ~1.56 nm versus ~0.60 nm, 
and ~2.92 nm versus ~0.51 nm in the pair of βAsp304-αLys326. 
    The attractions of other contributing charged residues, such as βArg213 and αAsp327, 
were also undermined as a result of VLB binding based on the alteration of DCOM 
between these two residues, by a separation of up to 0.86 nm versus ~1.85 nm. These 
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alterations were observable throughout the 115 ns trajectories. (Appendix A Figure A8 
D–F) 
    VLB and low temperature both alter the distribution of the electrostatic surface such 
that they weaken the longitudinal interactions of the tubulin heterodimer. 
 
Figure 2.10 The surface electrostatic potential map in vacuum of the unliganded and 
liganded αβ-heterodimer. The unliganded heterodimer at (A) 300 K and (B) 277 K. 
Negatively charged surface (red) and positively charged surface (blue). (C) and (D) are 
the close-up view of the selected area in (A) and (B), respectively. The surface 
electrostatic potential map in vacuum of (F) the unliganded and (G) the liganded αβ-
heterodimer at 300 K. (H) and (I) are the enlarged view of the selected areas in (F) and 
(G), respectively. (E) and (J) are residues contributing to the electron distribution in the 
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selected areas. Residues from the unliganded system at 300 K (gray stick), those of the 
unliganded system at 277 K as well as residues from the liganded system at 300 K (cyan 
ball-and-stick). Structures of each system are from the 100 ns frame of MD trajectories. 
 
2.4 Conclusions 
This work explores the possible binding site of doxorubicin at the αβ-tubulin heterodimer. 
We provide insights into the conformational changes of tubulin dimer imposed by 
binding to the anti-mitotic drug vinblastine, and a low temperature condition by means of 
molecular dynamics simulation. 
    The DNA targeted reagent doxorubicin showed favorable affinity to the αβ-tubulin 
heterodimer with the lowest binding free energy of -29.73 kJ/mol. The binding site of 
DOX predicted by Ghecom and FlexX is located at the edge of β-tubulin, surrounded by 
H1-S2 loop, T7 loop, and S9-S10 loop.  
    Taking into account the temperature variable in VLB-MT systems, this study has 
assessed various possible conformations of the heterodimer to fill the knowledge-gap 
between the data available from the low resolution crystal structures of tubulin and 
information from in vivo/in vitro experiments, for its applications on intensifying MT-
depolymerization process toward suppressing mitosis in cancerous cells. 
    Our computational calculation results are in line with the experimental data showing 
the compressive and bending modulus of MT at different temperatures (5-37 ºC) using 
atomic force microscopy, where the temperature-induced changes were correlated to the 
strength of lateral interactions between MT protofilaments.51 
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    In this study, VLB has been shown to have a major effect on folding H10 and S9 in α-
tubulin. Not only was the secondary structure of the segments around the binding pocket 
influenced by the binding of an anti-mitotic drug, but also H3 and H11 of α-tubulin as 
well as the H1-S2 loop of β-tubulin were altered, even though they were away from the 
binding site as shown in the variation of helicity percentage throughout the entire 
simulation time.  
    Low temperature of 277 K caused the unfolding of H5 and simultaneously resulted in 
the elongation of H3 and H11 in α-tubulin.  Reducing temperature also caused the partial 
unfolding of H7 to a simple coil in β-tubulin.  
    Interestingly, the two independent factors of temperature and an anti-mitotic agent in 
some regions of the protein facilitated similar changes, such as the formation of a new 
helix at T7 and the elongation of H10 in α-tubulin, the partial unfolding of H5 and 
formation of the β-hairpin at H1-S2 in β-tubulin. H1-S2, H3, T7 and H10 are functional 
segments; they are known to play key structural roles in depolymerization of MT 
protofilaments by involving in either the longitudinal or lateral contacts.  
    The α- and β-tubulin of the unliganded system at 277 K and those of the liganded 
system at 300 K are more water-exposed than those of the unliganded system at 300 K, 
indicating their overall destabilization effects on the heterodimer structure as a whole. 
The curvature of the dimer structure represented by the orientation of the central H7 
helices demonstrates the bent to straight conversion in the absence of VLB. By contrast, 
the liganded system maintains similar curved conformation as in the crystal structure due 
to the interactions of VLB with H7 in β-subunit. VLB presumably has a stronger effect 
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than low temperature on causing the loss of lateral contacts of H1-S2 loop in β-subunit 
based on the more prevalent folding change from a loop to a β-hairpin. Flexibility of the 
loop facilitates a larger number of interactions, hence, its folding to a more rigid β-hairpin 
results in decreasing the number of interactions and the destabilization at contact areas. 
    The distribution of the electrostatic potential map is altered by the variation of the 
distances among the contributing charged and polar amino acids in and around the VLB 
binding site as well as those at the interface of two subunits. The observations indicate 
weakening the longitudinal interactions as a result of VLB binding or reducing 
temperature from 300 to 277 K. 
    The insights of this study assist in better understanding the dynamics of tubulin 
depolymerization, caused by the chemotherapeutic agent vinblastine, and a physical 
factor such as temperature. The results are beneficial for developing more effective and 
tolerable drug-responsive and temperature-responsive therapeutic strategies to serve 
cancer patients through the inhibition of mitosis in cancerous cells. This study also 
provides foundational knowledge for developing effective drug delivery systems by 
taking into account specific chemical and environmental variables for increasing the 
drug–target sensitivity.  
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CHAPTER 3  
 
Interactions of Vinblastine with 
Single-Walled Carbon Nanotubes* 
3.1 Introduction 
Carbon nanotubes (CNTs) have been extensively studied in the last 25 years. They have 
shown tremendous applications in multiple disciplines, including composite material, 
microelectronics, energy storage, sensors, biomedicine and imaging.1-3 The medical 
applications of CNTs are especially inspiring for their prospective contribution to 
medicine. CNT-based carriers tailored for drug delivery have been extensively 
investigated and have shown promising outcomes.4-5 In general, nanoparticles are good 
vehicles for drug delivery as they can bind with drugs either by covalent conjugation or 
non-covalent absorption through π-π stacking6, hydrophobic effects7, or electrostatic 
interactions8. CNTs can bind drug molecules, protect them from degradation, transport 
them to cells and enter cells via endocytosis mechanism depending on the surface 
chemistry and dimensions of CNTs as well as cell types.9-11 They can accumulate in 
                                                 
* This chapter was based on “Molecular Dynamics Studies for Optimization of Noncovalent Loading of 
Vinblastine on Single-Walled Carbon Nanotube” Li, Z.; Tozer, T. & Alisaraie, L., The Journal of Physical 
Chemistry C 2016, 120, 4061-4070. Used with permission. 
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tumor tissues due to the enhanced permeability and retention (EPR) effect.  Modified or 
functionalized CNTs, as carriers, are particularly useful as they are less toxic than non-
functionalized CNTs12 and have higher solubility13. 
    Liu et al. compared the binding energy and drug release rate of the non-covalently 
loading doxorubicin (DOX) on poly(ethylene glycol) (PEG) functionalized SWNTs of ~ 
200 nm in length with two diameters:  ~ 1.3 and ~ 1.9 nm. They found that DOX on the 
larger tube had a higher affinity and was released with a slower rate due to the stronger π-
stacking with the larger tube.14 The same research group also functionalized SWNTs with 
phospholipids conjugated to branched PEG chains, and loaded paclitaxel (PTX) onto the 
carrier via cleavable ester bonds linking to the termini of PEG. An in vitro toxicity test on 
murine breast cancer 4T1 cells showed that the toxicity of SWNT-PTX was similar to 
clinical taxol and PEGylated PTX. The CNT-based delivery of PTX increased the blood 
circulation time much longer than the circulation time of taxol and PEGylated PTX, 
resulting in the high tumor accumulation through EPR effect. The high uptake of SWNT-
PTX significantly reduced the dose required for the desired efficacy, which in turn 
reduced toxic effects to normal cells. Based on the 4T1 breast cancer mouse model, 
SWNT-PTX had high efficiency in inhibiting proliferation and inducing apoptosis of 
tumor cells. The in vivo release of PTX was through the cleavage of ester bond by 
carboxylesterases, and the drugs and carriers were eliminated by the reticuloendothelial 
system.15 Kang et al. tested the cell response to SWNTs with the diameter of 1-3 nm with 
two different length ranges of 50-100 nm and 100-200 nm. The cellular uptake of short 
(less than 50 nm) SWNTs was through energy-independent insertion and diffusion. 
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SWNTs of 50-100 and 100-200 nm in length internalized cells through the endocytosis 
pathway. Folate conjugated functionalized SWNTs significantly improved the selectivity 
and efficiency of penetration into human hepatocellular carcinoma (human liver tumor 
cell line, commonly known as Hep G2) cells which over expressed folate receptors. On 
the other hand, the high uptake led to the enhanced cytotoxicity. SWNTs of 100-200 nm 
mainly distributed in cytoplasm, SWNTs of 50-100 nm could even internalize in the cell 
nucleus. They suggested that the appropriate length of SWNTs for targeted drug delivery 
purpose was around 200 nm.16 
    Compared to the abundant experimental studies on CNT-based drug delivery, only a 
few modelling studies related to the interactions between CNT and drug molecules have 
been reported. Hilder and Hill established models to calculate the suction energy of CNT 
for the maximum uptake of cisplatin, PTX and DOX, and to optimize the range of CNT 
radius for three individual drugs. But the model highly depended on the Lennard-Jones 
(LJ) potential, without considering the electrostatic potential and solvent effects.17-18 
SWNT-based in vitro or in silico delivery of Vinblastine (VLB), a prominent anti-mitotic 
drug used as widely as PTX and DOX for cancer treatment,19 has yet to be studied. Only 
one computational study by Mollaamin et al. reported comparisons of VLB–CNT 
stabilized energies mainly by quantum mechanics calculations for energy and geometry 
optimizations.20 The lack of thorough studies on the CNT-based delivery of VLB 
motivated us to explore the interactions of VLB with CNTs under different loading 
conditions and to investigate the influence of temperature change, functionalization and 
chirality of CNT on VLB–CNT interactions.  
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    Molecular dynamics (MD) simulation, a powerful and accurate computational 
technique, has been widely used to study the interactions of CNTs with biomolecules, 
polymers and drug molecules. For example, researchers have utilized MD simulations to 
study CNT-DNA interactions21, the wrapping of polyethylene on nanotube sidewall22, 
and the heat-driven drug release of the encapsulated ciprofloxacin23. As a continuation of 
our earlier studies on microtubules24-25, we investigated the chemo- and thermo-induced 
depolymerizing effects on αβ-tubulin heterodimer through MD simulations. Three 
systems were designed to compare the conformational changes of VLB-bound 
heterodimer at 300 K, apo-heterodimer at 277 K and apo-heterodimer at 300 K. The 
effects of VLB and low temperature were thoroughly studied from several perspectives, 
including conformational changes, structural stability as well as lateral and longitudinal 
contacts. We have found the thermo-effect is in line with the chemo-effect: they both 
triggered conformational changes resulting in the depolymerization of microtubules; 
furthermore, VLB displays stronger influence to disassemble microtubules than low 
temperature based on the overall effects on tubulin dimer structure. The studies 
foreshadowed the feasibility of a combinational therapy involving both therapeutics and 
temperature control for cancer treatment.26 
    The work presented in this chapter has made a step forward in the study of drug-carrier 
interactions under different conditions. MD simulations of VLB–SWNT non-covalent 
binding at 277 K and 300 K were performed to examine the effect of temperature on the 
CNT-based delivery of VLB. Additionally, our studies have provided in-depth 
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knowledge on drug–carrier interactions through the discussion of loading positions, 
interaction energy, loading capacities, CNT functionalization and chirality effects. 
 
3.2 Materials and Methods 
Considering the size of the VLB molecule (Appendix B Figure B1), the armchair (16, 16) 
SWNT, ~50 Å in length and 21.7 Å in diameter, was used as the carrier for the delivery 
of VLB, unless otherwise stated. SWNTs were functionalized by esterification27, through 
which four methyl ester groups covalently adjoined four carbon atoms at each end of the 
tube. (Appendix B Figure B2)  
Systems consisted of one CNT carrier and one to three VLB molecules attached to the 
exterior wall or encapsulated within the CNT. The CNT carrier is either non-
functionalized or functionalized, with a CNT of armchair, chiral or zigzag structure. 
(Table 3.1, Appendix B Figure B3 & Table B1, B2) 
 
 
 
 
 
 
 
 
81 
 
Table 3.1 Composition of various sets of CNT–VLB simulation systems. 
Systems 
VLB molecules loaded 
CNT Structure 
Amount Location 
SWNT-1VLB_Out 1 Outside Armchair (16, 16) 
Armchair (16, 16) 
Armchair (16, 16) 
Armchair (16, 16) 
Armchair (16, 16) 
Armchair (16, 16) 
Armchair (16, 16) 
Chiral (17, 15) 
Zigzag (28, 0) 
fSWNT-1VLB_Out 1 Outside 
SWNT-1VLB_In 1 Inside 
fSWNT-1VLB_In 1 Inside 
SWNT-2VLB_Out 2 Both outside 
fSWNT-2VLB_Out 2 Both outside 
fArmchair-3VLB 3 2 Outside, 1 Inside 
fChiral-3VLB 3 2 Outside, 1 Inside 
fZigzag-3VLB 3 2 Outside, 1 Inside 
 
    The optimized potentials for liquid simulations all-atom (OPLS-AA) force field28-31 
was utilized to perform simulations with Gromacs (version 4.5.5)32-33. The topology of 
VLB generated by ATB was based on Gromos96 force field 53A6,34 therefore the 
MKTOP35 was used to generate OPLS-AA topology for VLB. Partial atomic charge 
refinement was performed according to the chemical environment in VLB molecule and 
the corresponding atom type defined in OPLS-AA force field library. After charge 
refinement, the net charge of VLB was rounded to +1 due to the mono-protonation 
state.26 The refinement for bond and angle adapted by MKTOP program was 
implemented similarly as for the charge. The unrecognizable dihedrals in VLB were 
assigned by searching the closest dihedral type in terms of chemical environment 
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available in the OPLS-AA force field library and applying it to the matched dihedral type 
in VLB molecule.  
    SWNT structures were generated by Nanotube Modeler (version 1.7.3, JCrystalSoft).36 
The charge for carbon atoms of the pristine SWNT was zero based on the atom type 
defined for naphthalene in OPLS-AA force field. The bond type for carbon atoms in CNT 
was defined in the same way as in tryptophan, tyrosine and phenylalanine, the angle type 
was defined as a phenylalanine angle and the dihedral angle type as an aromatic ring 
dihedral angle.29-30 (Table 3.2)  
    The parameters for simulating CNT in this work agreed well with parameters used 
elsewhere.37-38 For the functionalized SWNTs (fSWNTs), the partial atomic charge for 
functional groups were assigned based on the atom type defined in OPLS-AA force field 
and adjusted to ensure the net neutral charge for the whole functional group. The 
parameters for angles and dihedrals in esterified SWNTs were undefined in the OPLS-
AA force field library. Therefore, parametrization was performed by searching the closest 
angle and dihedral types in terms of chemical environment available in the OPLS-AA 
force field parameters and applying them to fSWNTs. 
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Table 3.2 Parameters for simulating CNT using OPLS-AA force field. (kb, kθ and kφ are 
force constants of stretching, bending and torsional potentials. b0 and θ0 are reference 
geometry parameters. ε is the well depth, and σ is the separation distance at which the 
inter-particle potential is zero.) 
Items Parameters 
Bond kb = 392.4592 kJ mol–1 Å–2 b0 = 1.4 Å 
Angle kθ = 527.184 kJ mol–1 rad–2 θ0 = 120 ° 
Dihedral kφ = 30.334 kJ mol
–1  
Lennard-Jones ε = 0.29288 kJ mol–1 σ = 3.55 Å 
 
    The non-bonded interactions, including van der Waals (vdW) interactions and 
electrostatic interactions, were modelled by LJ potential and Coulomb potential, 
respectively.34 A cut-off distance of 1.0 nm was assigned for both Lennard-Jones and 
electrostatic interactions. The calculation of electrostatic forces and energies was carried 
out based on the Particle Mesh Ewald algorithm39. The LINear Constraint Solver (LINCS) 
algorithm40 was applied to constrain all bond lengths. The temperature was set to 277 K 
or 300 K with the temperature coupling of 0.1 ps. The time constant for pressure coupling 
was set to 1.0 ps with compressibility of 4.5e–5 bar–1.  
    Each simulation system was first energy minimized using the steepest descent 
algorithm and then a 4-ns all-bonds position restraint was applied. The MD simulations 
were implemented to gradually release constraints. The MD simulations for SWNT-
1VLB_In systems and fSWNT-1VLB_In systems were run for 350 ns. The MD 
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simulations for the two systems of fArmchair-3VLB at 300 K and fZigzag-3VLB at 277 
K were run for a total of 350 ns. Other simulations were run for 180 ns. All the 
simulations were performed on WestGrid high performance computer clusters of 
Compute Canada.41 (Table 3.1) 
 
3.3 Results and Discussions 
3.3.1 CNT-1VLB systems 
3.3.1.1 vdW force between VLB and SWNT 
For non-functionalized SWNT carrier, after convergence at ~150 ns, the stable LJ 
interactions of SWNT-1VLB_Out were -101.09 kJ/mol at 300 K and -119.65 kJ/mol at 
277 K. For fSWNT carrier, after convergence at ~150 ns, the stabilized LJ interactions of 
fSWNT-1VLB_Out were -121.80 kJ/mol at 300 K and -85.17 kJ/mol at 277 K. (Figure 
3.1) 
 
Figure 3.1 The LJ interactions between CNT and VLB for (A) SWNT-1VLB_Out and (B) 
fSWNT-1VLB_Out at 300 K (black) and 277 K (red), respectively. Arrow indicates one 
of the time frames corresponding to stable LJ energy. 
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    Before functionalization, VLB–CNT interactions were 18.6 kJ/mol stronger at 277 K 
than at room temperature. After functionalization, the trend was reversed: VLB–CNT 
interactions were 36.6 kJ/mol stronger at room temperature than at 277 K. Therefore, 
functionalization strengthened the SWNT–VLB interactions at room temperature but 
greatly weakened the interactions at 277 K. 
3.3.1.2 VLB orientations with respect to SWNT 
Temperature dramatically affected the level of stable interaction energy, for both non-
functionalized and functionalized SWNT carriers. The non-hydrogen atoms of vindoline 
and catharanthine components of VLB were numbered in two sequences42 to monitor the 
orientation of VLB with respect to SWNT surface. (Appendix B Figure B4)  
    VLB had the exterior-bound position parallel to the CNT surface, wherein both the 
vindoline and catharanthine sub-parts were ~ 3.5 Å away from the nearest CNT sidewall; 
or the exterior-bound position nonparallel to the CNT surface, wherein the vindoline sub-
part was ~ 3.5 Å away from the nearest CNT sidewall but the catharanthine sub-part was 
~ 7 Å away. When VLB had the parallel exterior-bound position, the co-planar structure 
of the aromatic ring and its adjacent pyrrole ring in vindoline flexibly changed the angle 
with SWNT surface such that the methyl ether group bound to C16 and the methyl group 
bound to N1 could orient either downward or upward to the SWNT surface. When VLB 
had the nonparallel exterior-bound position, the co-planar structure was no longer 
partially parallel to CNT sidewall but nearly perpendicular to the sidewall, which 
elevated the catharanthine part of VLB. (Figure 3.2)  
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    The distances between the CNT sidewall and atoms C6, C8, C26, O31, C8’, as well as 
O24’ in VLB were tracked over the entire simulation. (Appendix C Figure C1) 
    The similar parallel exterior-bound position in which C16 and N1 were facing away 
from the CNT shown in SWNT-1VLB_Out at 277 K and fSWNT-1VLB_Out at 300 K, 
resulting in a similar stable level of LJ interactions nearly -120 kJ/mol. However, the 
parallel exterior-bound position in which C16 and N1 facing downward the CNT shown 
in SWNT-1VLB_Out at 300 K, almost a flip-over pose of -119.65 kJ/mol parallel 
exterior-bound position, reduced LJ interactions to -101.09 kJ/mol. The nonparallel 
exterior-bound position shown in fSWNT-1VLB_Out at 277 K further reduced LJ 
interactions to -85.17 kJ/mol. (Figure 3.1 & 3.2)  
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Figure 3.2 Stable VLB orientations with respect to the CNT sidewall for SWNT-1VLB 
system at (A) 300 K and (B) 277 K, and for fSWNT-1VLB system at (C) 300 K and (D) 
277 K. Dashed lines indicate the nearest distance to the sidewall in Å. 
 
3.3.1.3 Encapsulation  
The stable LJ interactions for SWNT-1VLB_In at 300 K had energy levels of -239.66 
kJ/mol at 300 K and -179.33 kJ/mol at 277 K after convergence at ~ 300 ns. With 
functionalization, the LJ interactions for fSWNT-1VLB_In at 300 K and 277 K were 
stabilized at -206.09 kJ/mol and -206.23 kJ/mol, respectively. Functionalization reduced 
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the average stable LJ interactions at 300 K by 33.6 kJ/mol. Nevertheless, the average 
interactions between fSWNT and the encapsulated VLB at low temperature were 26.9 
kJ/mol stronger than those between non-functionalized SWNT and the encapsulated VLB. 
(Figure 3.3) 
 
Figure 3.3 The LJ interactions between CNT and VLB at (A) SWNT-1VLB_In and (B) 
fSWNT-1VLB_In under 300 K (black) and 277 K (red), respectively. Arrow indicates 
one of the time frames corresponding to stable LJ energy. 
 
    For non-functionalized SWNT carriers, the parallel encapsulated-bound position of 
VLB at 300 K led to stronger interactions with SWNT sidewall than the nonparallel 
encapsulated-bound position at 277 K. For fSWNT carriers, VLB had the parallel 
encapsulated-bound position at both 300 K and 277 K, leading to the almost equal 
strength of VLB–CNT interactions.  (Figure 3.4)  
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Figure 3.4 Stable orientations of encapsulated VLB with respect to CNT sidewall for 
SWNT-1VLB at (A) 300 K and (B) 277 K, and for fSWNT-1VLB at (C) 300 K and (D) 
277 K. Dashed lines indicate the nearest distance to the sidewall in Å.  
 
    Compared with the scenario that VLB was attached outside, the VLB–CNT 
interactions were much stronger when VLB was encapsulated. The strong encapsulated 
VLB–CNT interactions resulted from the large exposed surface area to VLB when it was 
encapsulated in the tube. The minimum distances between the CNT sidewall and VLB 
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atoms C21, C30, O31, C12’, C13’ as well as O24’ were tracked over the simulation. 
(Appendix C Figure C2) 
3.3.2 CNT-2VLB systems 
3.3.2.1 vdW force between VLB and SWNT 
An additional VLB was loaded onto the carrier in the CNT-2VLB systems. When the 
SWNT carrier was non-functionalized, the average LJ interactions for VLB1 and VLB2 
of SWNT-2VLB at 300 K were -83.91 kJ/mol and -100.62 kJ/mol, respectively, after 
convergence at ~150 ns. The stable LJ interactions for VLB1 and VLB2 of SWNT-2VLB 
system at 277 K were -117.65 kJ/mol and -84.08 kJ/mol, respectively. (Figure 3.5A-B) 
    For the functionalized carrier after convergence at ~ 150 ns, the average LJ interactions 
for VLB1 and VLB2 of fSWNT-2VLB at 300 K were -81.07 kJ/mol and -85.59 kJ/mol, 
respectively; and -81.85 kJ/mol and -80.96 kJ/mol, respectively, at 277 K. (Figure 3.5C-
D) 
91 
 
 
Figure 3.5 The LJ interactions between CNT and VLBs for SWNT-2VLB under (A) 300 
K and (B) 277 K as well as for fSWNT-2VLB under (C) 300 K and (D) 277 K, 
respectively. Arrow indicates one of the time frames corresponding to stable LJ energy. 
VLB1 is in black and VLB2 is in cyan. 
 
3.3.2.2 VLB orientations with respect to SWNT 
The orientations corresponding to different energy levels, approximately -80 kJ/mol, -100 
kJ/mol and -120 kJ/mol, were consistent with those shown in SWNT-1VLB_Out. The 
non-parallel exterior-bound position corresponded to LJ interaction of ~ -80 kJ/mol, as 
VLB1 in SWNT-2VLB at 300 K and VLB2 in SWNT-2VLB at 277 K. The parallel 
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exterior-bound position with C16 and N1 facing away from the CNT sidewall 
corresponded to LJ interaction of -117.65 kJ/mol, as VLB1 in SWNT-2VLB at 277 K; 
the parallel exterior-bound position with C16 and N1 facing toward the CNT sidewall 
corresponded to -100.62 kJ/mol, as VLB2 in SWNT-2VLB system at 300 K. (Figure 3.6)  
    The distances between the CNT sidewall and VLB atoms C26, O31, C5’, N6’, C11’, 
C21’ as well as O24’ were tracked over the entire simulation time. (Appendix D Figure 
D1) 
 
Figure 3.6 Stable orientations at SWNT-2VLB of (A) VLB1 and (B) VLB2 at 300 K as 
well as (C) VLB1 and (D) VLB2 at 277 K with respect to SWNT sidewall. Dashed lines 
indicate the nearest distance to the sidewall in Å. VLB1 is in gray and VLB2 is in cyan. 
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    All of the VLB molecules in fSWNT-2VLB had the nonparallel exterior-bound 
position at both temperatures. (Appendix D Figure D2)  
    The distances between the CNT sidewall and VLB atoms C6, O24, O31 as well as N6’ 
were tracked over the simulation. (Appendix D Figure D3) 
    When the temperature was changed from 300 K to 277 K for the non-functionalized 
system, the VLB1–CNT interactions were strengthened by 33.7 kJ/mol while the VLB2–
CNT interactions were weakened by 16.5 kJ/mol. However, the decrease of temperature 
did not affect the VLB–CNT interactions of the functionalized system. If the two VLB 
molecules were treated as indistinguishable, functionalization showed no effect to one of 
the VLB but weakened the interactions for the other VLB. The functionalization on CNT 
termini was not expected to affect the interactions of VLB with CNT sidewall. We 
elucidated that the undermined interactions were due to the loading capacity of the 
SWNT used. A CNT with the length of 50 Å may not be long enough to accommodate 
two dynamic VLB molecules with the dimension of 16 Å. The VLB–CNT interactions 
were weakened at both 300 K and 277 K, when an additional VLB was loaded onto the 
tube sidewall. (Figure 3.1 & 3.5) 
3.3.2.3 Inter-drug interactions 
In addition to the LJ interactions between CNT and VLB, the LJ and electrostatic 
interactions between the two VLB molecules loaded on SWNT-2VLB were also 
investigated. At 300 K, the maximum inter-drug LJ interactions were -25.5 kJ/mol and 
the maximum inter-drug electrostatic interactions were -9.8 kJ/mol for attractions and 
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+4.8 kJ/mol for repulsions. At 277 K, the maximum inter-drug LJ interactions were -35.9 
kJ/mol and the maximum inter-drug electrostatic interactions were -14.2 kJ/mol for 
attractions and +11.2 kJ/mol for repulsions. The inter-drug interactions existed only when 
the center-of-mass (COM) distance between VLB1 and VLB2 was less than 2 nm. The 
interactions vanished at the COM distance greater than 2 nm. (Appendix D Figure D4) 
    For fSWNT-2VLB systems at 300 K, the maximum inter-drug LJ interactions were -
24.1 kJ/mol and the maximum inter-drug electrostatic interactions were -5.8 kJ/mol for 
attractions and +6.7 kJ/mol for repulsions. At 277 K, the maximum inter-drug LJ 
interactions were -29.9 kJ/mol and the maximum inter-drug electrostatic interactions 
were -7.0 kJ/mol for attractions and +7.5 kJ/mol for repulsions. The inter-drug 
interactions existed only when the COM distance between VLB1 and VLB2 was below 2 
nm. The LJ and Coulomb interactions reached the maximum approximately at the time 
corresponding to the minimum COM distance. (Appendix D Figure D5) 
3.3.3 CNT-3VLB systems 
The CNT-3VLB systems include three sub-systems: fArmchair-3VLB, fChiral-3VLB 
and fZigzag-3VLB; each sub-system was studied at 277 K and 300 K. 
3.3.3.1 fArmchair-3VLB 
3.3.3.1.1 vdW force between VLB and SWNT 
For the functionalized armchair SWNT carrier, the stable LJ interactions for VLB1, 
VLB2 and VLB3 of fArmchair-3VLB at 300 K were -116.72 kJ/mol, -199.13 kJ/mol and 
-230.01 kJ/mol, respectively, after convergence at ~150 ns. At 277 K, the stable LJ 
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interactions for VLB1, VLB2 and VLB3 were -121.98 kJ/mol, -203.37 kJ/mol and -
101.77 kJ/mol, respectively, after convergence at ~150 ns. (Figure 3.7) 
 
Figure 3.7 The LJ interactions between CNT and VLBs at fArmchair-3VLB under (A) 
300 K and (B) 277 K, respectively. Arrow indicates one of the time frames corresponding 
to stable LJ energy. VLB1 is in black, VLB2 is in green and VLB3 is in cyan. 
 
3.3.3.1.2 VLB orientations with respect to fArmchair SWNT 
At 300 K, VLB1, initially set outside the tube, continuously moved along the exterior of 
the tube during the simulation in the parallel exterior-bound position; VLB2, initially 
encapsulated in the tube, continuously moved in the tube during the entire simulation 
time; VLB3, initially set outside the tube, entered the tube shortly after the start of the 
simulation (~1 ns) and remained encapsulated during the rest of the simulation time. 
(Figure 3.8)  
    The distances between the CNT sidewall and VLB atoms C7, C8, C22, C13’ as well as 
C21’ were tracked over the simulation. (Appendix E Figure E1) 
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Figure 3.8 Stable orientations of (A) VLB1, (B) VLB2 and (C) VLB3 at 300 K with 
respect to fArmchair SWNT. Dashed lines indicate the nearest distance to the sidewall in 
Å. VLB1 is in gray, VLB2 is in green and VLB3 is in cyan. 
 
    In fArmchair-3VLB at 300 K, VLB3 entered the tube from outside; the noteworthy 
phenomenon did not occur in the CNT-1VLB systems or the CNT-2VLB systems. The 
key factors that likely triggered this event were LJ and Coulomb interactions between 
fArmchair SWNT and VLB3. The entering process, from ~ 0.4 ns to ~ 1 ns, was 
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accompanied by a dramatic increase in LJ interactions. The strong LJ interactions played 
a key role in encapsulating the VLB3 molecule, which was in line with the studies on 
DNA encapsulation by SWNT.43 The electrostatic attractions between the methyl ester 
groups and VLB3, although weak (~3.5 kJ/mol), could be significant in directing and 
pulling VLB3 into the tube. (Figure 3.9, Appendix E Figure E2)   
    VLB2, the already encapsulated drug molecule, did not appear to play a role in the 
encapsulation of VLB3. This was because there were not any inter-drug interactions 
between VLB2 and VLB3 as the COM distance was above the 2-nm threshold during the 
entering process of VLB3.   
 
Figure 3.9 (A) LJ and (B) Coulomb interactions between fArmchair SWNT and VLB3 in 
the process of VLB3 entering the tube. 
 
    At 277 K, VLB1 and VLB3, initially set outside the tube, continuously moved along 
the exterior of the tube during the simulation and had the parallel exterior-bound position; 
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VLB2, initially encapsulated in the tube, continuously moved inside the tube during the 
entire simulation time. (Appendix E Figure E3)  
    The distances between the CNT sidewall and VLB atoms C8, O24, C33, C8’ as well as 
C21’ were tracked over the simulation. (Appendix E Figure E4) 
3.3.3.1.3 Intermolecular drug interactions 
When VLB molecules distributed both outside and inside the tube, the CNT sidewall 
acted as a shield by greatly weakening the inter-drug LJ and electrostatic interactions 
between the attached VLB and the encapsulated VLB. For fArmchair-3VLB at 300 K, 
both LJ and Coulomb interactions were significant for the two VLB molecules inside the 
tube. However, the interactions of VLB2 and VLB3 with VLB1 outside the tube were 
negligible. At 277 K, both LJ and Coulomb interactions were significant for the two VLB 
molecules VLB1 and VLB3 outside the tube, however, their interactions with VLB2 in 
the tube were negligible. (Appendix E Figure E5)  
    The shielding effect from CNT sidewall was further verified by the COM distance 
among the three VLB molecules. When the COM distance was below 2 nm, only both 
VLB molecules located either outside the tube or inside the tube would interact with each 
other. Even when two VLB molecules are close enough to each other, such as VLB1 
outside ~1.5 nm from VLB2 inside at 277 K, no interactions were observed. Without the 
sidewall barrier, LJ and Coulomb interactions reached the maximum approximately at the 
same time as the minimum COM distance. (Appendix E Figure E6) 
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3.3.3.2 fChiral-3VLB 
3.3.3.2.1 vdW force between VLB and SWNT 
For functionalized chiral SWNT carrier, the stable LJ interactions for VLB1, VLB2 and 
VLB3 of fChiral-3VLB at 300 K were -83.79 kJ/mol, -204.56 kJ/mol and -116.28 kJ/mol, 
respectively, after convergence at ~150 ns. At 277 K, the stable LJ interactions for VLB1, 
VLB2 and VLB3 were -102.87 kJ/mol, -208.10 kJ/mol and -121.59 kJ/mol, respectively. 
The decrease of temperature made VLB1–CNT interactions stronger, but showed little 
effects on the encapsulated VLB2 and the attached VLB3. (Figure 3.10) 
 
Figure 3.10 The LJ interactions between CNT and VLBs in fChiral-3VLB at (A) 300 K 
and (B) 277 K, respectively. Arrow indicates one of the time frames corresponding to 
stable LJ energy. VLB1 is in black, VLB2 is in green and VLB3 is in cyan. 
 
3.3.3.2.2 VLB orientation with respect to fChiral SWNT 
At 300 K, VLB1, initially attached to the exterior of the tube, continuously stayed outside 
during the entire simulation time and had the nonparallel exterior-bound position. VLB2, 
100 
 
initially encapsulated in the tube, continuously stayed in the tube during the entire 
simulation time. VLB3, initially attached outside the tube, continuously stayed outside 
and had the parallel exterior-bound position. (Appendix E Figure E7)  
    The distances between the CNT sidewall and VLB atoms C8, C26, O31, C5’, C12’ as 
well as O24’ were tracked over the simulation. (Appendix E Figure E8) 
    At 277 K, VLB1 and VLB3, initially located outside the tube, continuously stayed 
outside during the simulation process and had parallel exterior-bound positions; VLB2, 
initially encapsulated in the tube, continuously moved inside the tube during the entire 
simulation time. (Appendix E Figure E9)  
    The distances between the CNT sidewall and VLB atoms O24, C33, C12’, C14’ as 
well as O24’ were tracked over the simulation. (Appendix E Figure E10) 
3.3.3.2.3 Inter-drug interactions 
The shielding effect by CNT sidewall on both electrostatic and LJ interactions was also 
observed in fChiral-3VLB at 300 K and 277 K, LJ and Coulomb interactions were 
significant only for VLB1 and VLB3 both located outside the tube. (Appendix E Figure 
E11)  
    When the COM distance was within 2 nm, only VLB molecules located outside the 
tube interacted with each other. (Appendix E Figure E12) 
3.3.3.3 fZigzag-3VLB systems 
3.3.3.3.1 vdW force between VLB and SWNT 
For functionalized zigzag SWNT carrier, the stable LJ interactions for VLB1, VLB2 and 
VLB3 of fZigzag-3VLB at 300 K were -100.44 kJ/mol, -211.06 kJ/mol and -120.87 
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kJ/mol, respectively, after convergence at ~150 ns. At 277 K, the stable LJ interactions 
for VLB1, VLB2 and VLB3 were -84.24 kJ/mol, -223.66 kJ/mol and -192.01 kJ/mol, 
respectively. The large increase of LJ interactions for VLB3 at 277 K system resulted 
from the encapsulation. (Figure 3.11) 
 
Figure 3.11 The LJ interactions between CNT and VLB molecules of fZigzag-3VLB at 
(A) 300 K and (B) 277 K, respectively. Arrow indicates one of the time frames 
corresponding to stable LJ energy.  
3.3.3.3.2 VLB orientations with respect to fZigzag SWNT 
At 300 K, VLB1 and VLB3, initially located outside the tube, continuously stayed 
outside and had the parallel exterior-bound position. VLB2, initially encapsulated in the 
tube, continuously moved inside the tube during the simulation. (Appendix E Figure E13)  
    The distances between the CNT sidewall and VLB atoms C8, O24, C33, C8’, C21’ as 
well as O24’ were tracked over the simulation. (Appendix E Figure E14) 
    At 277 K, VLB1, initially located outside the tube, continuously moved outside and 
had the nonparallel exterior-bound position. VLB2, initially encapsulated in the tube, 
continuously moved inside the tube during the entire simulation time. VLB3, initially 
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located outside the tube, entered the tube at ~ 3 ns and remained encapsulated during the 
rest of the simulation time. (Appendix E Figure E15)  
    The distances between the CNT sidewall and VLB atoms C8, C21, C33, C5’, C13’ as 
well as O24’ were tracked over the simulation. (Appendix E Figure E16) 
3.3.3.3.3 Inter-drug interactions 
The inter-drug interactions in fZigzag-3VLB were similar to those observed in the other 
CNT-3VLB systems. The encapsulation of VLB3, observed in fArmchair-3VLB at 300 K, 
also happened to the VLB3 of fZigzag-3VLB at 277 K. VLB3 entered the tube during 
~1.5 ns to ~ 5.5 ns. The entering process was longer than that of the VLB3 of fArmchair-
3VLB at 300 K. The key factors facilitating the encapsulation were LJ and Coulomb 
interactions between fZigzag SWNT and VLB3. VLB3 completely entered the tube at ~ 
3.5 ns and remained at the end of the tube until ~ 6 ns before it moved further to the 
interior of the tube. (Appendix E Figure E17, E18) 
    Hilder and Hill deduced that the optimum SWNT radius to encapsulate paclitaxel and 
doxorubicin ranged from 9.13 to 12.68 Å and 8.86 to 10.51 Å, respectively, which were 
18.26-25.36 Å and 17.72-21.02 Å in diameter, respectively.18 The CNT diameter used in 
this study (~ 21.8 Å) is in the optimized range of paclitaxel encapsulation and just 
slightly above the upper limit of doxorubicin entry. However, this diameter is clearly not 
ideal because VLB molecules can be encapsulated and trapped in the CNTs. The two 
VLB molecules, entered the tube in two independent systems, were trapped in the interior 
during the extended simulation up to 350 ns. (Appendix E Figure E19)  
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    The encapsulation was irreversible due to the intensive interactions nearly twice as 
strong as that in the external attachment, consequently, encapsulation prevented the 
unloading of VLB. The irreversible encapsulation phenomenon observed in these 
investigations was consistent with studies of fullerene encapsulation through the open 
end of armchair (10, 10) SWNT reported by Berber and co-workers.44 The remedy for 
removing the unloading hurdle caused by encapsulation lies in shrinking the tube 
diameter to block VLB entry so that all drug molecules are loaded to the exterior wall and 
delivered and unloaded to the target without being trapped inside the tube. The 
encapsulation that occurred in this study was quite rare, which is consistent with the 
findings by Berber et al.44 Optimization requires a balance between small tube diameter 
to avoid drug encapsulation and large exterior surface area to enhance the interactions 
between the drug and the carrier. Further studies are needed in order to find an optimized 
diameter range for SWNTs to enable strong drug–carrier interactions that can overcome 
all barriers in the transportation process and to ensure the majority of VLB molecules are 
delivered to the target site. 
3.3.4 Interaction energy levels 
Throughout different systems, VLB had three stable orientations with the exterior tube 
sidewall. The nonparallel exterior-bound position with the low interaction energy of 
nearly -80 kJ/mol mainly involved interactions between the vindoline moiety of VLB and 
the sidewall. The parallel exterior-bound position gave a medium interaction energy of 
nearly -100 kJ/mol and involved interactions between both catharanthine and vindoline 
moieties of VLB and the sidewall, with C16 and N1 facing toward the tube. The parallel 
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exterior-bound position with higher interaction energy of nearly -120 kJ/mol involved the 
interactions of both sub-parts of VLB with the sidewall, with C16 and N1 facing away 
from the tube. Unlike the attachment-mode, the movement of VLB inside the tube under 
the encapsulation mode was more flexible. Interestingly, VLB displayed the three 
orientations described in the attachment-mode in one trajectory under the encapsulation 
mode, the interaction energy fluctuated accordingly. Compared to the small portion of the 
curved exterior sidewall exposed to the VLB attached to the outside of a tube, more 
surface area was available to VLB under encapsulation which resulted in a much stronger 
interaction energy of nearly -210 kJ/mol. (Figure 3.12) 
 
Figure 3.12 The stable orientations of VLB corresponding to different energy levels. 
3.3.5 Effect of functionalization 
Functionalization of CNT termini affects the strength of the drug–carrier interactions. At 
300 K, CNT esterification in a system with one VLB molecule strengthened the VLB–
CNT interactions by 20.7 kJ/mol. In a system with two VLB molecules, the 
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functionalization weakened the VLB–CNT interactions of one VLB molecule by 15.0 
kJ/mol, but did not affect the other VLB molecule. Moreover, in CNT–3VLB, with two 
VLB molecules initially positioned outside the tube and one VLB encapsulated inside, 
upon the transition of one of the VLB molecules from outside the tube into the tube, 
functionalization of the CNT showed an increase of 15.6 kJ/mol in VLB–CNT 
interactions for the VLB that remained outside the tube. Therefore, functionalization 
enhanced the drug–carrier interactions when only one VLB was loaded outside the tube. 
For multiple payloads, it is inferred that the strength was also affected by the loading 
capacity of the carrier and that, upon functionalization, the interactions would be 
strengthened with sufficiently long tube. 
    Nevertheless, at 277 K, when one drug was loaded, functionalization weakened the 
interactions by 34.5 kJ/mol. When two VLB molecules were loaded, functionalization did 
not affect one VLB molecule but weakened the interactions for the other VLB by 35.8 
kJ/mol, which had a greater effect compared with the system at 300 K. In the system with 
three VLB molecules, functionalization weakened the interactions for one of the 
molecules outside the tube by 17.9 kJ/mol but did not affect the other VLB outside the 
tube. Overall, functionalization weakened the drug-carrier interactions at 277 K.  
    The encapsulated molecules were not affected by esterification of the CNT as the 
structure of the side with which they interacted was not influenced by modifications on 
tube ends. Based on these observations, it is proposed that longer CNTs would have a 
larger loading capacity for the attachment of drug molecules. The esterified 
functionalization would strengthen the interactions at 300 K and most VLB molecules 
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would orient in the parallel exterior-bound position with the most stable energy level. 
Alternatively, at 277 K, if attached to a longer tube, most VLB molecules would likely 
orient in the nonparallel exterior-bound position with the least stable energy level. 
    The high toxicity of pristine CNTs45-46 can be reduced by functionalization. The 
introduction of polar groups would also increase the solubility and dispersion of CNTs. 
CNT functionalization is an essential step leading to the manufacture of commercial 
CNT-based drug carriers. 
3.3.6 Effect of temperature 
In non-functionalized systems, the VLB-CNT interactions in CNT-1VLB_Out and the 
overall VLB–CNT interactions in SWNT-2VLB were enhanced at 277 K. Conversely, 
the lower temperature weakened the VLB–CNT interactions in CNT-1VLB_In. 
    In functionalized systems, the lower temperature reduced the VLB–CNT interactions 
for the VLB attached to the exterior of the tube but did not affect the VLB inside the tube. 
For a system with two VLB molecules loaded outside the tube, the lower temperature did 
not affect the VLB–CNT interactions.  
    In functionalized systems with three VLB molecules, the reduced temperature did not 
influence the encapsulated VLB, however, it showed different effects on the attached 
VLB molecules depending on the chirality of CNTs. In the armchair CNT system, one of 
the two attached VLB molecules entered the tube, the lower temperature did not affect 
VLB–CNT interactions for the VLB molecule that remained outside the tube. In the 
chiral CNT system, the lower temperature slightly increased the interactions for one of 
the VLB molecules by 19.1 kJ/mol. In the zigzag CNT system, one of the two attached 
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VLB molecules entered the tube, while the lower temperature slightly decreased the 
interactions for the VLB molecule that remained outside the tube by 16.2 kJ/mol. 
Therefore, aiming for the delivery of multiple drug molecules by functionalized CNT, the 
functionalized armchair CNT is the best option for the delivery at room temperature and 
277 K. At 277 K, the enhanced drug-carrier interactions make functionalized chiral CNTs 
a particularly good choice for delivery at temperatures below 300 K. 
3.4 Conclusions 
In this chapter, the stable orientations of VLB with respect to the CNT carrier, and the 
effect of temperature change as well as CNT structure on several different VLB–CNT 
systems with one to three VLB molecules have been discussed. VLB showed three stable 
orientations on the CNT sidewall under the attachment loading mode, which 
corresponded to three energy levels with low, medium and high strength of interactions 
with the energy gap between each orientation of ~ 20 kJ/mol. The encapsulation mode of 
loading VLB could be challenging for drug release to the target, as all VLB molecules 
placed inside the tube remained encapsulated during the entire simulation. The stable 
VLB orientations have been observed among all three different types of CNT carriers, 
and chirality shows slight impact on drug orientations due to the different arrangement of 
carbon atoms. When the diameter of CNT is large enough to accommodate a VLB 
molecule into the tube, with the proper orientation and strong interactions, a VLB 
molecule can enter the tube and become trapped. This occurred to one of the VLB 
molecules attached to the functionalized armchair CNT at 300 K and to the 
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functionalized zigzag CNT at 277 K. These simulations provide clues to design 
appropriate CNT-based drug-carriers so that unwanted encapsulation can be avoided. 
    Functionalization is necessary to reduce the toxicity of CNT and to improve the 
biocompatibility with biological systems, and it would likely enhance the VLB–CNT 
interactions of a longer CNT with higher loading capacity at 300 K. In terms of the 
possible temperature-adapted cancer treatment, the functionalized armchair CNT is a 
good option for the drug delivery at both 277 K and 300 K because of the relatively 
strong drug–carrier interactions. The functionalized chiral CNT is especially suitable for 
VLB delivery at 277 K.  
    Overall, this study has revealed the interactions of VLB with CNT in various systems, 
which offers fundamental knowledge for the design and optimization of CNT-based 
carriers for VLB delivery. 
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CHAPTER 4  
 
Summary 
In this thesis, the possible binding site of doxorubicin at the αβ-tubulin heterodimer has 
been explored. The conformational changes of tubulin dimer triggered by the anti-mitotic 
drug VLB and the low temperature condition have been unveiled by means of MD 
simulation. The similar responses of tubulin heterodimer to both VLB and low 
temperature provide clues toward establishing novel strategies on combatting cancer 
diseases.  
    The stable orientations of VLB with respect to the CNT carrier as well as the effects of 
CNT structure and temperature change on several different VLB–CNT systems have also 
been discussed. These simulations provide guidance to design appropriate CNT carriers 
to avoid drug molecules being trapped inside the tube. Based on the fundamental 
knowledge revealed through the interactions of VLB with CNT in various systems, it is 
proposed that the functionalized armchair CNT is appropriate for the drug delivery at 277 
K as well as 300 K, and the functionalized chiral CNT is suitable for VLB delivery at 277 
K.  
    Future perspectives based on this work are summarized in the following two aspects. 
First, the DOX–MT system is worthwhile for further investigations using MD simulation 
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to elucidate more detailed interactions and ligand-induced conformational changes, by 
taking into account flexibilities of both protein and DOX in solution phase similar to the 
VLB–MT system as it has been discussed in Chapter 2. Second, the VLB–CNT research 
was the first phase of our project to study SWNTs as carriers for the drug whose delivery 
has not been examined so far. Hence, the fundamental knowledge to explore design rules 
is required to develop the project to a more advanced level. Further simulations could be 
carried out on CNTs longer than 50 Å with various diameters in order to compare the 
modelling results with in vitro experimental studies on CNT-based drug delivery systems.
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 Appendix A 
 
Figure A1 VLB geometry in (A) crystal structure of 4EB6 and (B) the first ranked 
docking solution. Some interacting residues from α-tubulin (yellow) and β-tubulin (green) 
are shown at the binding pocket. (C) Front and (D) back view of the 1st ranked (gray) and 
6th ranked (green) docking poses. The protonated nitrogen is highlighted in a sphere. 
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Figure A2 Helicity plots of H3, the new helix formed at T7 loop, H10 and H11 in α-
tubulin comparing the unliganded and liganded system at 300 K. 
 
120 
 
 
Figure A3 Helicity plots of H5 in β-tubulin comparing the unliganded and liganded 
systems at 300 K. 
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Figure A4 Helicity plots of H3, H5, the new helix formed at T7 loop, H10 and H11 in α-
tubulin comparing the unliganded systems at 300 K and 277 K, respectively.  
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Figure A5 Helicity plots of H3, H5 and H7 in β-tubulin comparing the unliganded 
system at 300 K and 277 K, respectively. 
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Figure A6 SASA of the loop H1-S2 in three systems changing over the course of the 
simulation time. 
  
124 
 
 
Figure A7 The curvature of αβ-tubulin heterodimer represented by H7 orientation of the 
unliganded heterodimer at (A) 300 K, (B) 277 K and of (C) the liganded heterodimer at 
300 K from the 2nd round simulations. The angles indicate the average deviation of 
heterodimers shifting from the curved conformation in the crystal structure. The inset 
scheme at (C) describes the structure caused by VLB with more bending than the crystal 
structure. 
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Figure A8 The distance between the charged residues contributing to the electrostatic 
surface. Each panel is a comparison of a pair of charged residues under two different 
conditions. The dashed line indicates the convergence point. 
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Table A1 The top 10 docking solutions of the mono-protonated VLB ranked by FlexX. 
Rank 
Score 
(kJ/mol) 
Match 
(kJ/mol) 
Lipophilic 
(kJ/mol) 
Ambiguous 
(kJ/mol) 
Clash 
(kJ/mol) 
RMSD (Å) 
1 -8.0814 -13.0764 -13.542 -8.5235 4.8606 6.3851 
2 -6.2647 -14.7242 -11.4641 -9.289 7.0126 10.7734 
3 -6.1923 -15.6398 -12.7842 -9.3892 9.4209 8.6124 
4 -5.3067 -15.6806 -13.5578 -9.0258 10.7575 8.1732 
5 -4.4144 -12.9817 -16.1357 -9.473 11.9761 7.5182 
6 -3.7758 -10.6882 -12.59 -7.3485 4.6505 6.3335 
7 -3.4799 -12.7875 -13.0774 -7.8528 8.0378 8.3967 
8 -3.3683 -15.5418 -9.7845 -8.9348 8.6928 9.1038 
9 -2.0776 -15.5224 -13.6993 -8.3718 13.3159 7.4438 
10 -1.9751 -10.7183 -11.3053 -6.2374 4.0859 8.8255 
Score: total score of the docking solution 
Match: contribution of the matched interacting groups 
Lipophilic: contribution of the lipophilic contact area 
Ambiguous: contribution of the lipophilic-hydrophilic (ambiguous) contact area 
Clash: contribution of the clash penalty 
RMSD: RMSD of coordinates from reference coordinates 
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 Appendix B 
 
Figure B1 Size of VLB showing in a 3D box. 
 
 
Figure B2 Esterification of SWNT.
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Figure B3 Initial configurations of CNT-1VLB system (A1, attached VLB; A2, 
encapsulated VLB), CNT-2VLB system (B) and CNT-3VLB system (C, fZigzag used as 
an example). Double arrow lines indicate the length and diameter of the armchair SWNT. 
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Figure B4 Chemical structure of mono-protonated VLB. 
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Table B1 Dimensional parameters of SWNT. 
CNT type Armchair (16, 16) Chiral (17, 15) Zigzag (28, 0) 
Length (Å) 50 50 50 
Diameter (Å) 21.7 21.7 21.9 
 
 
Table B2 Diameter of six armchair SWNTs. 
Armchair CNT Diameter (Å) 
(11, 11) 14.927 
(12, 12) 16.283 
(13, 13) 17.64 
(14, 14) 18.977 
(15, 15) 20.354 
(16, 16) 21.711 
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 Appendix C 
 
Figure C1 The distances between selected VLB atoms and CNT sidewall over the 
simulation for the non-functionalized and functionalized SWNT-1VLB_Out systems. 
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Figure C2 The minimum distances of selected VLB atoms to CNT sidewall for the non-
functionalized and functionalized SWNT-1VLB_In over the entire simulation time.  
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 Appendix D 
  
Figure D1 The distances between selected atoms in VLB1 and VLB2 and CNT sidewall 
for SWNT-2VLB at 300 K (above red dashed line) and 277 K (below red dashed line). 
VLB1 is in black and VLB2 in cyan. 
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Figure D2 Stable orientations of (A) VLB1 and (B) VLB2 at 300 K as well as (C) VLB1 
and (D) VLB2 at 277 K with respect to fSWNT sidewall. Dashed lines indicate the 
nearest distance to the sidewall in Å. VLB1 is in gray and VLB2 is in cyan. 
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Figure D3 The distances between selected atoms in VLB1 and VLB2 and CNT sidewall 
for fSWNT-2VLB at 300 K (above dashed red line) and 277 K (below dashed red line). 
VLB1 is in black and VLB2 is in cyan. 
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Figure D4 LJ and Coulomb interactions between VLB1 and VLB2 in SWNT-2VLB_Out 
at (A) 300 K and (C) 277 K. The corresponding COM distance between VLB1 and VLB2 
changing from 150 to 180 ns at (B) 300 K and (D) 277 K. The inset close-up depicts a 
range where both interactions are significant. Vertical dashed lines indicate the time 
frame with relatively strong LJ and Coulomb interactions. Arrows indicate the time 
corresponding to the minimum COM distance. 
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Figure D5 LJ and Coulomb interactions between VLB1 and VLB2 in fSWNT-
2VLB_Out at (A) 300 K and (C) 277 K. The corresponding COM distance of VLB1 and 
VLB2 from 150 to 180 ns at (B) 300 K and (D) 277 K. The enlarged inset in (A) and (C) 
depict a range where both interactions are significant. Vertical dashed lines indicate the 
time frame with relatively strong LJ and Coulomb interactions. Arrows indicate the time 
corresponding to minimum COM distance. 
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 Appendix E 
 
Figure E1 The distances between selected atoms in VLB1, VLB2 and VLB3 and CNT 
sidewall for fArmchair-3VLB at 300 K. VLB1 is in black, VLB2 is in green and VLB3 is 
in cyan. (same color code as below) 
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Figure E2 Four frames in the process of VLB3 entering fArmchair SWNT at 300 K. 
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Figure E3 Stable orientations of (A) VLB1, (B) VLB2 and (C) VLB3 at 277 K with 
respect to fArmchair SWNT. Dashed lines indicate the nearest distance to the sidewall in 
Å. 
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Figure E4 The distances between selected atoms in VLB1, VLB2 and VLB3 and the 
CNT sidewall for fArmchair-3VLB at 277 K. 
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Figure E5 The inter-VLB LJ interactions at (A) 300 K and (C) 277 K as well as the inter-
VLB Coulomb interactions at (B) 300 K and (D) 277 K for fArmchair-3VLB. 
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Figure E6 The inter-VLB COM distances among VLB1, VLB2 and VLB3 changing 
from 150 to 180 ns for fArmchair-3VLB at (A) 300 K and (C) 277 K. The significant 
inter-VLB interactions at (B) 300 K and (D) 277 K. Arrows indicate the time 
corresponding to the minimum COM distance. 
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Figure E7 Stable orientations of (A) VLB1, (B) VLB2 and (C) VLB3 at 300 K with 
respect to fChiral SWNT. Dashed lines indicate the nearest distance to the sidewall in Å. 
VLB1 is in gray, VLB2 is in green and VLB3 is in cyan. 
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Figure E8 The distances between selected atoms in VLB1, VLB2 and VLB3 and the 
CNT sidewall of fChiral-3VLB at 300 K. 
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Figure E9 Stable orientations of (A) VLB1, (B) VLB2 and (C) VLB3 at 277 K with 
respect to fChiral SWNT. Dashed lines indicate the nearest distance to the sidewall in Å. 
VLB1 is in gray, VLB2 is in green and VLB3 is in cyan. 
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Figure E10 The distances between the selected atoms in VLB1, VLB2 and VLB3 and 
the CNT sidewall for fChiral-3VLB at 277 K.  
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Figure E11 The inter-VLB LJ interactions at (A) 300 K and (C) 277 K as well as the 
inter-VLB Coulomb interactions at (B) 300 K and (D) 277 K for fChiral-3VLB. 
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Figure E12 The inter-VLB COM distances changing from 150 to 180 ns for fChiral-
3VLB at (A) 300 K and (C) 277 K. The significant VLB1-VLB3 interactions at (A) 300 
K and (C) 277 K. Numbers indicate the time corresponding to the minimum COM 
distance. 
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Figure E13 Stable orientations of (A) VLB1, (B) VLB2 and (C) VLB3 at 300 K with 
respect to fZigzag SWNT. Dashed lines indicate the nearest distance to the sidewall in Å.  
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Figure E14 The distances between the selected atoms in VLB1, VLB2 and VLB3 and 
the CNT sidewall for fZigzag-3VLB at 300 K. 
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Figure E15 Stable orientations of (A) VLB1, (B) VLB2 and (C) VLB3 at 277 K with 
respect to fZigzag SWNT. Dashed lines indicate the nearest distance to the sidewall in Å.  
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Figure E16 The distances between the selected atoms in VLB1, VLB2 and VLB3 and 
the CNT sidewall for fZigzag-3VLB at 277 K. 
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Figure E17 Four frames in the process of VLB3 entering fZigzag SWNT at 277 K. 
 
 
Figure E18 (A) LJ and (B) Coulomb interactions between fZigzag SWNT and VLB3 in 
the process of VLB3 entering the tube. 
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Figure E19 The LJ interactions between CNT and VLB molecules of (A) fArmchair-
3VLB at 300 K and (B) fZigzag-3VLB at 277 K, after the convergence of MD 
simulations until the extension to 350 ns. VLB1 is in black, VLB2 is in green and VLB3 
is in cyan. 
 
 
